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ABSTRACT 
 
Papillary and Follicular thyroid carcinomas (PTC and FTC) are lesions derived from follicular cells. 
The standard therapy includes surgery and radioiodine treatment. Despite being usually associated with 
a good prognosis the rate of recurrence is high and a subset of patients present radioiodine refractory 
and non-responsive neoplasia. So, the search for new therapeutic alternatives, as well as new 
diagnostic/prognostic markers is highly relevant. 
Our group at IPOLFG has previously shown RAC1b to be overexpressed in PTCs, being this 
overexpression significantly associated with poorer outcomes. RAC1b is a variant of the small GTPase 
RAC1 that was shown to have the ability to stimulate the canonical NF-κB regulatory pathway in 
colorectal cancer. NF-κB activation is associated with the tumorigenic process in several types of cancer, 
mainly due to its role in apoptosis evasion.  
Here, we aimed to extend the study of the role of RAC1b to FTCs and further investigate the 
molecular mechanisms associated with RAC1b overexpression and downstream signalling in thyroid 
tumorigenesis. 
Using the human papillary thyroid carcinoma derived cell line as in vitro model, we observed that 
both RAC1 and RAC1b were able to induce a significant increase on NF-κB and cyclin D1 reporter 
activity. A clear p65 nuclear localization was found in cells transfected with RAC1b-WT, confirming 
NF-κB canonical pathway activation. Consistently, we were able to observe a RAC1b-mediated 
decrease in IκBα (NF-κB inhibitor) protein levels.  
These findings prompted us to further assess the cellular consequences of RAC1b-mediated NF-κB 
activation in a thyroid biological system. Our results indicated that RAC1b protected cells against 
apoptosis and stimulated G1/S progression, through a process involving the NF-κB pathway. 
Summing up, presented findings suggest an important role of RAC1b in the progression of follicular 
cell derived thyroid carcinomas and point out NF-κB activation as one of the molecular mechanisms 
associated with RAC1b overexpression and downstream signalling in thyroid tumorigenesis. 
 
 
 
Key words: Thyroid tumorigenesis; RAC1b; NF-κB canonical pathway; Cyclin D1; Apoptosis; 
Cell Cycle;  
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RESUMO 
 
O Carcinoma Papilar (CPT) e o Carcinoma Folicular da Tiróide (CFT) são lesões derivadas de 
células foliculares. A terapia de referência inclui cirurgia e tratamento com iodo radioativo. Apesar de 
estarem normalmente associados a um bom prognóstico, o nível de recorrências é elevado dado que um 
subconjunto de pacientes apresentam neoplasias refratárias ou incapazes de responder ao iodo 
radioativo. Portanto, a busca por alternativas terapêuticas, bem como novos marcadores de 
diagnóstico/prognóstico é bastante relevante.  
O nosso grupo no IPOLFG identificou anteriormente a sobre-expressão do RAC1b em CPTs, e esta 
sobre-expressão estava significativamente associada com um pior prognóstico. O RAC1b é uma variante 
da pequena GTPase RAC1, que demonstrou a capacidade de estimular a via canónica do NF-κB em 
cancro colo-retal. A ativação do NF-κB está associada com o processo tumorigénico em vários tipos de 
cancro, maioritariamente devido ao seu papel na evasão da apoptose.  
O objetivo do presente estudo foi o de expandir o estudo do papel do RAC1b aos CFT, e ainda 
investigar os mecanismos moleculares subjacentes à sobre-expressão do RAC1b e sinalização a jusante 
na tumorigénese da tiróide  
Usando uma linha celular derivada de CPT como modelo in vitro, observou-se que quer o RAC1, 
quer o RAC1b mostraram capacidade de induzir um aumento significativo na atividade do repórter do 
NF-κB e da ciclina D1. Uma clara localização nuclear da proteína p65 foi observada em células 
transfetadas com GFP-RAC1b-WT, confirmando a ativação da via canónica do NF-κB. 
Consistentemente, observou-se uma diminuição mediada pelo RAC1b dos níveis proteicos de IκBα (um 
inibidor do NF-κB).  
Estes resultados levaram-nos a avaliar as consequências celulares da ativação do NF-κB mediada 
pelo RAC1b no sistema biológico da tiróide. Os nossos resultados indicam que o RAC1b protegeu as 
células contra a apoptose e estimulou a progressão G1/S, através de um mecanismo que envolve a via 
do NF-κB. 
Resumindo, as presentes conclusões apontam para um importante papel do RAC1b no 
desenvolvimento de CFTs e indicam a ativação do NF-κB como um dos mecanismos moleculares 
associados com a sobre-expressão do RAC1b e sinalização a jusante na tumorigénese da tiróide.  
 
 
 
 
Palavras-Chave: Tumorigénese da Tiróide; RAC1b; Via canónica do NF-κB; Ciclina D1; 
Apoptose; Ciclo celular;  
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I. INTRODUCTION 
 
1. Tumorigenesis  
 
The pursuit for an explanation about the basis of malignant changes has started many years ago with 
several studies being reported. For example, back to 1974, Loeb and collaborators indicated errors in 
DNA replication as a possible cause of malignant events. Nevertheless, in the last few years, several 
scientific advances took place in the cancer research field allowing the scientific community to better 
understand the biological mechanisms involved in the genesis of tumours – Tumorigenesis.  
Modifications in the control and homeostatic balances that regulate a myriad of cellular processes, 
namely proliferation, differentiation and apoptosis are considered the primary sources of malignant 
changes (Koeffler et al., 1991). The idea that genetic alterations are required to tumorigenesis is widely 
accepted, and evidences that tumours accumulate numerous genetic changes, such as chromosomal 
abnormalities, gene mutations and epigenetic alterations has been shown over the years (Loeb et al., 
1974; Koeffler et al., 1991; Bach et al., 2000; Hanahan and Weinberg, 2000; Sieber et al., 2003; 
MacConaill and Garraway, 2010).  
Despite the vast diversity of existing tumours, some intrinsic features may be shared and considered 
universal features of all tumours. Back to 2000, Hanahan and Weinberg proposed six essential 
modifications in cell physiology required in the tumorigenesis process (see Figure I.1): self-sufficiency 
in growth signals, insensitivity to anti-growth signals, evasion to apoptosis, unlimited replicative 
potential, sustained angiogenesis and ability to invade tissues and metastasize. These features allowed 
tumour cells to generate their own signals and, in opposition, to escape of anti-proliferative signals. The 
unlimited replicative potential contributes to the immortalization of tumour cells that guarantee a 
continuous nutrient supply by create their own blood vessel network.  
 
Figure I.1. The 
hallmarks of cancer. 
Adapted from Hanahan 
and Weinberg (2000) and 
Hanahan and Weinberg 
(2011). 
 
 
 
 
 
 
 
 
 
- 2 - 
 
In addition to these common and widely accepted features, recently new characteristics were 
proposed as hallmarks of cancer (see Figure I.1): cellular energy metabolism adaptation and ability to 
evade immune system (Hanahan and Weinberg, 2011; Serpa and Dias, 2011).  
In fact, tumour cells have an altered metabolism relative to normal cells (Serpa and Dias, 2011). 
The increased proliferative potential of tumour cells requires higher rates of metabolic reactions in order 
to obtain nutrients, energy and biosynthetic activity (DeBerardinis et al., 2008; Tennant et al., 2009; 
Tennant et al., 2010). This phenotype allows tumour cells to have an increased rate of glycolysis 
(conversion of glucose to pyruvate), either in aerobic or anaerobic conditions (Tennant et al., 2009), 
which compensates the limited levels of oxidative phosphorylation in some regions of solid tumours 
(Frezza and Gottlieb, 2009). 
To progress, tumour cells have to be able to evade immune system. The interaction between the 
malignant cells and the cells of the immune system has different stages – elimination, equilibrium and 
escape – and this process is known as cancer immunoediting. In the elimination or cancer surveillance 
phase, transformed cells are identified and killed by the innate and the adaptive immune system. These 
events result in an immune selection that is favourable to tumour variants with increased ability to 
withstand immune factors and decrease immunogenicity. The equilibrium phase is known by the 
persistence of the tumour cells that were not killed, but also can not expand due to the immune pressure. 
When the tumour is able to growth due to the immune exhaustion or inhibition, or as result of  emerging 
tumour-cell variants  able to evade immune pressure, the escape stage is ongoing (Dunn et al., 2006; 
Kim et al., 2007).   
Several lines of evidence, suggest that human tumorigenesis is a multiset process (Hanahan and 
Weinberg, 2000) in which normal cells are progressively transformed in malignant derivatives. The 
progression through the many stages of this process depends on several factors, such as genomic 
instability, which is inherent to some cancers, or the ability of these tumours to promote inflammation 
that occasionally support multiple hallmark capabilities (Sieber et al., 2003; Hanahan and Weinberg, 
2011). 
 
2. Thyroid gland: Anatomy and physiology  
 
The thyroid gland, part of the endocrine system, is a butterfly-shaped organ consisting of two lobes 
positioned on either side of the trachea, connected by a structure named isthmus (see Figure I.2). Despite 
the variance in the size and appearance of the adult gland, - according to functional activity, gender, 
hormonal status, and iodine intake - the thyroid gland is one of the largest glands in the body, weighing 
approximately 15 to 25 g (Muro-Cacho and Ku, 2000; Nussey and Whitehead, 2001).   
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The primary role of this organ in the 
development of vertebrates is related with 
its ability to synthesize hormones that are 
crucial for growth, development and 
survival, due to their capacity to convey 
oxygen and nutrients into cells and convert 
them into energy. Two of the thyroid-
synthesized hormones with higher impact 
are tetraiodothyronine (thyroxine or T4) 
and triiodothyronine (T3). The storage of 
thyroid hormones occurs mainly within the 
follicles, the functional unit of the thyroid 
gland (Nussey and Whitehead, 2001; Nitsch 
et al., 2010). The synthesis of thyroid hormones requires the iodination of tyrosine molecules (Nussey 
and Whitehead, 2001), and their activity is mediated by thyroid hormone receptors, which exists in 
different isoforms (Gauthier et al., 1999; Zhu et al., 2010; Kim and Cheng, 2013). In fact, the iodine 
represents an essential element in thyroid physiology and function, and its uptake in the thyroid gland 
is mediated by the sodium/iodide symporter (NIS) (Filetti et al., 1999; Kogai et al., 2006). 
The thyroid embryogenesis involves an initial step in which this gland develops from the anterior 
foregut, following a sequence of morphogenetic steps that culminate in the migration of the thyroid bud 
to its final anatomic position (Fagman and Nilsson 2010a). This developmental process and the final 
thyroid fate are influenced by the combined expression of specific transcription factors by foregut 
endoderm cells (Fagman and Nilsson 2010a; Fagman and Nilsson 2010b). 
Several cell types, derived from the three germ layers, compose the thyroid gland (Damante and 
DiLauro, 1994). The most abundant cellular population are the follicular cells that are associated with 
the production of thyroid hormones and surround the follicles (see Figure I.2) - oval sacs filled with 
colloid (Ljungberg et al., 1983; Damante and DiLauro, 1994; Muro-Cacho and Ku, 2000). The C cells, 
or parafollicular cells, are associated with calcitonin production (Ljungberg et al., 1983; Muro-Cacho 
and Ku, 2000). 
 
3. Thyroid diseases and syndromes 
 
The thyroid gland is subject of a multitude of diseases and syndromes that impair the function of 
this gland, for example, goitres, hyper- and hypo-thyroidism, thyroiditis, Graves’ disease and cancer 
(Muro-Cacho e Ku, 2000). Thyroid nodules are considered common and present a risk of malignancy 
(approximately 5%). The enormous challenge in this field is related with the management of this nodules 
and the evaluation of treatment needs (Gharib et al., 2007). Generally, the medical approach includes 
Figure I.2. Location and structure of the thyroid gland. 
Adapted from http://www.cancer.ca/en/cancer-information/cancer-
type/thyroid/anatomy-and-physiology/?region=bc 
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the evaluation only of nodules larger than 1 cm or nodules smaller than 1 cm in which the patient 
revealed suspicious ultrasound findings, a history of head and neck irradiation, or a positive family 
history of thyroid cancer (Cooper et al., 2006). However, the controversy surrounding this subject 
prevails (Gharib et al., 2007). 
 
3.1. Thyroid neoplasia 
 
Thyroid tumours account for approximately 1% of worldwide human malignant neoplasms, 
(Schlumberger, 1998; Biersack and Grünwald, 2005). Nevertheless, they represent the most common 
(almost 90%) malignancy in the endocrine system (Biersack and Grünwald, 2005; Siegel et al., 2013). 
Thyroid cancer is most prevalent among women (the incidence ratio male: female is approximately 1:3), 
is rare in children and the age of diagnosis varies between 20-50 years (Schlumberger, 1998; DeLellis 
et al., 2004; Biersack and Grünwald, 2005; Vriens, 2009). Despite the higher incidence in women, some 
reported studies underline a worse prognostic perspective in man (Yao et al., 2011). 
Numerous statistical studies have described an increasing incidence of thyroid cancer (Cramer et 
al., 2010), namely in the United States where it was estimated the appearance of approximately 45000 
new cases of thyroid cancer, in 2010 (Jemal et al., 2010). The debate in this field continues on whether 
or not this increase is only a consequence of a more efficient diagnostic surveillance and pathologic 
recognition (DeLellis et al., 2004; Cramer et al., 2010). This hypothesis is supported by the reported 
decrease in mortality rate that prove the impact of more sensitive and efficient diagnostic methods 
(DeLellis et al., 2004).  
The good prognosis associated with most thyroid neoplasia can be explained by its low cell 
proliferative cellular rate and is also probably related with the advances in the knowledge of factors that 
influence the malignant progression (DeLellis et al., 2004; Biersack and Grünwald, 2005). The standard 
therapy for most thyroid carcinomas includes total thyroidectomy followed by radioiodine treatment and 
close follow up, which is effective for most of the cases. However, a subset of patients with 
advanced/dedifferentiated malignancy are unresponsive or refractory to radioiodine management, which 
are closely related to high recurrence and mortality levels (Sonkar et al., 2010; Soares et al., 2014).      
The development and progression of thyroid malignancies are influenced by diverse factors, that 
can be environmental, hormonal or genetic as well as by the interaction between all of the above 
(DeLellis et al., 2004).   
Thyroid neoplasia can be divided in different groups with remarkably different features. Firstly, it 
is possible to distinguish benign lesions, known as adenomas (follicular thyroid adenoma – FTA), from 
malignant lesions, called carcinomas (Muro-Cacho and Ku, 2000). Thyroid carcinomas comprise two 
groups based on cell type from which they develop: thyroid cancers that arise from follicular cells 
(thyroid hormone-producing) that are called non-medullary thyroid carcinomas (NMTCs) and represent 
approximately 95% of all tumours; carcinomas that arise from C cells (calcitonin-producing) and are 
known as medullary thyroid carcinomas (MTCs), representing 3–5% of all tumours (Muro-Cacho and 
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Ku, 2000; Capezzone et al., 2008; Nikiforov and Nikiforova, 2011). The large majority of NMTCs are 
well-differentiated and classified as papillary (papillary thyroid carcinoma-PTC) or follicular (follicular 
thyroid cancinoma-FTC). The minor portion of NMTCs show a poorly differentiated (poorly 
differentiated thyroid carcinoma-PDTC) or undifferentiated (anaplastic thyroid carcinoma-ATC) 
phenotype (Liu et al., 2006; Morani et al., 2014).  
 
3.1.1. Medullary Thyroid carcinoma 
 
The medullary thyroid carcinoma arises from C cells (calcitonin-producing) and accounts for a 
modest percentage of all thyroid tumours (3-10%) (Dvorakova et al., 2008; Nikiforov and Nikiforova, 
2011). Most of MTC are sporadic (75% of all cases), however 25% of the cases can be associated with 
a familial predisposition (autosomal dominant). The familial forms can occur either as familial MTC 
(FMTC – isolated event) or as part of multiple endocrine neoplasia type 2 (MEN 2) syndromes. The 
MEN 2 syndromes and FMTC are usually associated with germline gain of function mutations in the 
RET proto-oncogene, which can also occur somatically, associated with the sporadic form of MTC 
(Dvorakova et al., 2008). This form may also be associated with RAS point mutations that seem to work 
as alternative genetic events for the activating mutations of RET in sporadic MTC (Moura et al., 2011). 
 
3.1.2. Non-Medullary Thyroid tumours 
 
As previously denoted, non-medullary thyroid tumours are lesions with origin in the follicular cells 
representing about 95% of all thyroid malignancies. The lesions can be grouped in concordance with 
the differentiation degree of follicular cell - Well Differentiated Thyroid Carcinoma (WDTC), Poorly 
Differentiated Thyroid Carcinoma (PDTC) and Anaplastic Thyroid Carcinoma (ATC). The WDTC 
group are composed by two different histologic types of tumours – papillary and follicular (see Figure 
I.3) (Muro-Cacho and Ku, 2000; Liu et al., 2006; Capezzone et al., 2008; Morani et al., 2014).  
Tumours associated with less differentiation of follicular cells are usually the most aggressive and 
also associated with poor prognosis due to the lack of therapies available (Kondo et al., 2006). While 
these malignancies can arise de novo, some reported studies support the hypothesis that all of these 
tumours share an evolutionary link, in which papillary and follicular thyroid carcinomas may give rise 
to the poorly differentiated and anaplastic forms, through a stepwise process of dedifferentiation of 
papillary and follicular carcinomas (Bhaijee and Nikiforov, 2011; Caronia et al., 2011; Nikiforov and 
Nikiforova, 2011). The majority of known genetic alterations associated with papillary and follicular 
thyroid carcinoma fall into one of four mutually exclusive groups (Bhaijee and Nikiforov, 2011): BRAF 
[Murine sarcoma viral (v-raf) oncogene homolog B1] and RAS (Rat sarcoma vírus homolog) point 
mutations, and RET/PTC (RET- rearrangement during transfection) and PAX8/PPARγ [paired box 
gene 8 (PAX8)-peroxisome proliferator-activated receptor γ (PPARγ)] rearrangements.  It is known that 
thyroid cancer initiation and progression involve an accumulation of different types of genetic 
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alterations. The same probably happens in the dedifferentiation process in which some mutations that 
represent early events in thyroid cancer progression (such as BRAF and RAS mutation), that are found 
either in WDTC or in PDTC/ATC, may predispose WDTC to dedifferentiation. 
 
 
 
 
Figure I.3. Subtypes of non-meddulary thyroid carcinomas. Adapted from Nikiforov and Nikiforova (2011) and Sastre-
Perona and Santisteban (2012). 
 
 
3.1.2.1. Follicular thyroid adenoma 
 
Benign tumours of thyroid gland are designated by follicular thyroid adenomas (FTA). This group 
of tumours is characterized by their encapsulated form (usually a fibrous capsule of variable thickness) 
and they are round or oval, measuring between 1 and 3 cm. This lesion can occur in normal glands or in 
association with thyroiditis, nodular hyperplasia or other lesions. Typically FTAs present follicular cell 
differentiated phenotype (Muro-Cacho and Ku, 2000; DeLellis et al., 2004; Liu et al, 2006). It has been 
also proposed that FTA may serve as a precursor for some follicular carcinomas (Nikiforov and 
Nikiforova, 2011). 
 
3.1.2.2. Follicular thyroid carcinoma 
 
Follicular thyroid carcinoma is a type of malignant tumours that represents approximately 10-15% 
of all thyroid cancers (Bhaijee and Nikiforov, 2011; Sobrinho-Simões et al., 2011). According to the 
WHO (World Health Organization) Classification of Tumours of Endocrine Organs, FTC can be defined 
as ‘a malignant epithelial tumour showing follicular cell differentiation and lacking the diagnostic 
nuclear features of papillary thyroid carcinoma’ (see DeLellis et al., 2004). These are commonly solid 
tumours presenting as an isolated focus (unifocal), encapsulated, characterized by haematogenous 
spread, exhibiting less lymph node involvement (than PTCs), and with size higher than 1 cm 
(Schlumberger, 1998; DeLellis et al., 2004; Kondo et al., 2006; Romitti et al., 2013). As PTCs, follicular 
carcinomas can also be divided in different variants, namely the conventional type and the oncocytic 
type (oxyphilic or Hürthle cells tumours) (Schlumberger, 1998; Bhaijee and Nikiforov, 2011; Bonora et 
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al., 2010). The invasion grade of the capsule and vessels (infiltrative growth) is a distinguishing feature 
between follicular carcinomas and follicular adenomas. The classification of tumours according to its 
pattern of invasion recognized two groups – those minimally invasive and the widely invasive 
carcinomas (Schlumberger, 1998; Biersack and Grünwald, 2005; Bonora et al., 2010). 
The most common genetic alterations associated with FTCs (70-75% of cases) are RAS point 
mutations and PAX8/PPARγ rearrangements which are mutually exclusive (DeLellis et al., 2004; Castro 
et al., 2006; Bhaijee and Nikiforov, 2011; Sobrinho-Simões et al., 2011).  
The prognosis of FTC depends on several features, namely the age of the patients at the diagnosis 
(usually higher comparing to PTCs), tumour size and stage, invasion rate, extensiveness of surgery and 
responsiveness to radioactive iodine (Muro-Cacho and Ku, 2000; DeLellis et al., 2004; Kondo et al., 
2006).  
One of the biggest challenges in this field is related with the pre-surgical discrimination between 
malignant follicular thyroid cancer and benign follicular thyroid adenoma. Although the gold standard 
for evaluating thyroid nodules is fine needle aspiration (FNA) biopsy, this method is unable to reliably 
distinguish FTC from FTA, since the key feature associated with this malignancy is its invasiveness rate 
(capsular and/or vascular penetration) (Schlumberger, 1998; Barden et al., 2003; DeLellis et al., 2004). 
Thyroid unilateral lobectomy is still used as a standard approach which allows a postsurgical diagnosis 
as FTC or FTA. Depending on the postsurgical conclusion, patients are managed in different ways - 
only cancer patients require completion total thyroidectomy, adjuvant radioiodine treatment, and long-
term follow-up (Pfeifer et al., 2013). The big challenge is to find a reliable method to discriminate FTC 
and FTA in FNA material. Over the years numerous studies proposed different immunohistochemical 
markers. Pfeifer and collaborators (2013) reported a panel of five genes (ELMO1, EMCN, ITIH5, 
KCNAB1, SLCO2A1) with a 72% specificity grade; 94% accuracy was found in a six gene set 
(TFF3/PLAB/TG/ADM3/HGD1/LGALS3) (Krause et al., 2008). Many other studies were performed, 
namely studies assessing the use of miRNAs as potential distinguish markers (Stokowy et al., 2014) or 
studies where metabolomics approach were used (Deja et al., 2013). Despite all the efforts, no panel of 
molecular markers with confidence levels of specificity and sensitivity that allows the preoperative 
discrimination between FTCs and FTAs has been defined yet. 
 
3.1.2.3. Papillary thyroid carcinoma 
 
PTC is the most common malignant epithelial thyroid tumour presenting differentiation of follicular 
cell – PTC integrates the WDTC group. Papillary tumours account to nearly 80% of all thyroid cancers 
(DeLellis et al., 2004; Caronia et al., 2011). This tumour type is usually associated with good prognosis 
and long-term survival rates, due to a successful combination of radioiodine and levothyroxine treatment 
following total thyroidectomy. However, up to 10% patients would eventually die of the disease mostly 
due to the high levels of recurrences, since a subset of patients with advanced stage carcinomas have 
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radioiodine refractory and non-responsive malignancies (Sonkar et al., 2010; Soares et al., 2014). Older 
age at diagnosis, male gender, large tumour size and extra-thyroidal growth represent the most relevant 
poor prognostic factors (DeLellis et al., 2004; LiVolsi, 2011; Soares et al., 2014).  
Most of papillary lesions are firm masses with the size ranging from less than 1 mm to several 
centimetres. The prominent papillae are a specific feature of this type of lesion, such as enlargement, 
oval shape, elongation and overlapping of the nuclei (DeLellis et al., 2004).  
Papillary thyroid neoplasia is influenced by environmental, genetic and hormonal factors. 
Environmental factors comprise genotoxic (DNA damage due to radioactive iodine) and non-genotoxic 
effects (due to iodine deficiency). The thyroid dependency of iodine makes it vulnerable to radiation, 
being the PTC the subtype mostly linked to this factor (DeLellis et al., 2004). 
PTC can be divided into numerous histopathologic variants based on specific growth patterns, cell 
types and stromal changes (Lloyd et al., 2011) – for example, follicular variant of papillary thyroid 
carcinoma (FVPTC) preserves nuclear features similarly to PTC, but exhibits a predominantly micro-
follicular histologic growth pattern (McFadden et al., 2014). 
Point mutations (such as mutations in the RAS and BRAF genes) and the RET/PTC and PAX8/PPARγ 
chromosomal rearrangements are common genetic alteration in this cancer subtype, that usually involve 
the effectors of the MAPK (Mitogen-activated protein kinases) and PI3K-AKT (PI3K– phosphoinositide 
3-kinase; AKT – Protein Kinase B) pathways (Nikiforov and Nikiforova, 2011). Rearrangements in the 
RET proto-oncogene, known as RET/PTC, can be detected in PTCs with its prevalence varying between 
different patient cohorts – from 20% of all cases to much higher percentages (DeLellis et al., 2004; 
Nikiforov and Nikiforova, 2011). The V600E mutation on the BRAF proto-oncogene is the most 
frequent genetic alteration in PTC, representing 40-50% of cases (Nikiforov and Nikiforova, 2011). 
V600E – a transversion resulting in the substitution of glutamic acid for valine - is the most common 
BRAF mutation (Lee et al., 2007; Caronia et al., 2011). RAS point mutations can also be found, but the 
reported prevalence is much smaller – 10-20% according to Nikiforov and Nikiforova (2011). The 
indicated numbers can be much different in the others variants of PTC, namely on FVPTC, where a 
different and less prevalent type of BRAF mutation (K601E) can be found. Also, PAX8/PPARγ 
rearrangements and RAS point mutation have a higher prevalence than in classic PTC subtype – 40% 
and 25% of all FVPTC cases, respectively (Castro et al., 2006). 
BRAFV600E mutation in PTC 
BRAF is a serine/threonine kinase of the RAF family of proteins and it’s considered a strong 
activator of the MAPK pathway (involved in the regulation of several cellular responses) (Davies et al., 
2002; Lee et al., 2007). BRAF mutations are not specific of thyroid tumours and are also highly prevalent 
in malignant melanoma, colorectal carcinoma and serous ovarian cancer (Garnett and Marais, 2004). 
BRAFV600E mutation is generally accepted as the most frequent genetic alteration in PTCs. This mutation 
constitutively activates BRAF kinase, which works as a prolonged stimuli of the MAPK pathway, 
culminating in an increase of cell proliferation and defective apoptotic levels (Davies et al., 2002; Soares 
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et al., 2003; Wan et al., 2004).  The association between BRAF mutation and morphological and 
functional alterations related with PTC phenotype has been reported, for example, the presence of 
papillary structures that are a characteristic of the classical variant of PTCs are a phenotypic feature 
closely associated with BRAFV600E-positive tumours (Lee et al., 2007; Rusinek et al., 2011). Significant 
correlation between BRAF mutations and extra-thyroidal invasion, lymph node metastasis, and tumour 
stage has been also reported in PTC by Chakraborty and collaborators (2012). 
 
3.1.2.4. Poorly differentiated thyroid carcinoma 
 
Poorly differentiated thyroid carcinoma is a rare entity that represents less than 10% of all NMTC 
(Biersack and Grünwald, 2005; Bonora et al., 2010). As already mentioned, this is a neoplasia originated 
from thyroid follicular cells, representing an intermediate morphological and biological behaviour 
between well-differentiated thyroid carcinomas and anaplastic thyroid carcinomas (Muro-Cacho and 
Ku, 2000; DeLellis et al., 2004; Biersack and Grünwald, 2005). This type of malignancy affects more 
males than WDTC and the average age of onset is higher, at approximately 50 years old. Lymph nodes 
and distant metastasis are highly frequent. The survival rates are low in the first three years after the 
diagnosis, and lower after five years, precisely due to metastasis occurrence (30-80%) (DeLellis et al., 
2004; Biersack and Grünwald, 2005; Kondo et al., 2006).  Kondo and collaborators (2006) documented 
RAS and TP53 (Tumour protein 53) mutations as the most frequent genetic alterations in PDTC (18-
27% and 17-38% of all cases, respectively). BRAF point mutation are also present in some cases (0-
13%) supporting the hypothesis of a WDTC to PDTC transition.    
 
3.1.2.5. Anaplastic thyroid carcinoma 
 
Anaplastic carcinoma is a highly malignant tumour composed by undifferentiated cells in a partial 
or total undifferentiated form. This type of malignancy represents less than 5% of all NMTC cases, 
being the least common form (Muro-Cacho and Ku, 2000; DeLellis et al., 2004; Bonora et al., 2010). 
ATCs are highly aggressive and lethal tumours with a very low survival rate – the mean duration of 
survival is only months (DeLellis et al., 2004; Biersack and Grünwald, 2005; Kondo et al., 2006; Soares 
et al., 2011). These tumours can coexist with other thyroid carcinomas or hyperplasia (30% of the cases), 
and are usually non-encapsulated tumours, extensively invading the perithyroid tissues. The three main 
morphological patterns are squamoid, pleomorphic giant cell and spindle cell (Kondo et al., 2006; 
Soares et al., 2011). The mean age at the time of initial diagnosis is about 60 years old and there is a 
higher frequency on females (Muro-Cacho and Ku, 2000; DeLellis et al., 2004; Kondo et al., 2006; 
Soares et al., 2011). Mutations in the tumour suppressor gene p53 are known as the most common 
genetic events in this type of malignancy (67-88%) (Kondo et al., 2006). 
 
 
 
- 10 - 
 
4. RAC1 and RAC1b GTPases 
 
4.1. Organization and regulation 
 
RAC1 is a member of the Rho (Ras homologous) family of small guanosine triphosphatases 
(GTPases) – a subgroup of the RAS superfamily of GTP (Guanosine triphosphate)-binding proteins. 
This Rho GTPases family includes other members such as Rho and Cdc42 (Cell division control protein 
42 homolog). RAC1 protein is encoded by RAC1 gene and can exist in two different conformational 
states - an inactive GDP (Guanosine diphosphate)-bound form and an active GTP-bound form (Jordan 
et al., 1999; Matos et al., 2000; Wennerberg and Der, 2004; Jaffe and Hall, 2005).  
The interconversion between the two states occurs through a cycle of guanine exchange and GTP 
hydrolysis, wherein GTP binding induces a conformational change that involves two important 
regulatory regions, termed Switch I and Switch II. Consequently, the switch regions provide a surface 
that, in the active state, enables their interaction with downstream effectors, allowing these GTPases to 
function as molecular switches (Wennerberg et al., 2005). This cycling process is tightly regulated by 
several groups of proteins: Rho-GEFs (Guanine exchange factors) which promote exchange of GDP for 
GTP; Rho-GAPs (GTPase activating protein) that enhance the hydrolysis of bound GTP to GDP and 
inorganic phosphate, regulating in the inactivation of the GTPases; GDP dissociation inhibitors (GDI) 
are also regulatory proteins that sequester Rho GTPases in the cytoplasm in an inactive GDP-bound 
state, preventing exchange of GDP to GTP (Jordan et al., 1999; Bernards and Settleman, 2004; Singh et 
al., 2004).  
 
Figure I.4. Diagram of the RAC1 gene. 1, 2, 3, 4, 5, 6 represent exons. Adapted from Matos et al., 2000. 
 
Back to 1999, Jordan and collaborators performed a RT-PCR (Reverse transcription polymerase 
chain reaction) based assessment of RAC1 expression in colorectal samples (tumours and normal 
mucosa) that leads to the identification of a new RAC1 splicing variant, termed RAC1b. This variant was 
also found to be expressed in breast carcinomas (Schnelzer et al., 2000). The RAC1b isoform results 
from an alternative splicing event that leads to the inclusion of an additional exon (exon 3b). This 
additional exon is inserted between exons 3 and 4 (see Figure I.4) of  RAC1  and contains 57 additional 
nucleotides that result in an in-frame insertion of 19 amino acid residues between codons 75 and 76, in 
the vicinity of the switch II domain (Jordan et al., 1999).  
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RAC1b is considered a highly activatable variant of RAC1: despite the lower levels of expression 
compared to RAC1, RAC1b exists predominantly in the active GTP-bound state. This is essentially due 
to RAC1b disability to interact with Rho-GDI, which keeps this GTPase constitutively membrane-
bound, a location that benefits the interaction with activators, and consequently promotes the active 
GTP-bound state (Matos et al., 2003). Moreover, RAC1b shows impaired intrinsic activity and increased 
GDP to GTP exchange rates, although this variant can still be downregulated by activated GAPs and it 
is influenced by GEFs action (Schnelzer et al., 2000; Matos et al., 2003; Fiegen et al., 2004; Singh et 
al., 2004). Also, RAC1b's additional amino acids seem to confer to this variant a selective downstream 
signalling, since several pathways activated by RAC1, are not activated by RAC1b (Matos et al., 2003).  
 
4.2. Biological functions 
 
The Rho family of small GTPases  is known to play an important role in several cellular processes, 
namely in actin cytoskeleton reorganization – Cdc42 regulates the formation of filopodia; RAC1 is 
involved in the lamellipodia formation; RhoA promotes the formation of stress fibres (Fukuda et al., 
2002; Matos et al., 2003; Singh et al., 2004).  
RAC1, in particular, has the ability to interact with specific effectors, inducing activation of 
numerous signalling cascades that culminate in different physiological outcomes, namely cytoskeletal 
dynamics alteration, progression through the cell cycle  and cell proliferation, apoptosis, migration and 
cell-cell adhesion, membrane trafficking and superoxide production (Matos et al., 2000; Jaffe and Hall, 
2005; Bosco et al, 2009). There are several downstream effectors and signalling proteins influenced by 
activated RAC1, namely WAVE (WASP-family verprolin-homologous protein) complex, PAK (p21 
activating kinase) and LIM. For example, GTP-bound RAC1 binds to PAK1, stimulating its protein 
kinase activity, which allows the interaction with other proteins, leading to the modulation of several 
biological activities, such as the mentioned actin reorganization (Jaffe and Hall, 2005; Bosco et al, 2009; 
Nagase and Fujita, 2013). 
The action of activated RAC1 also includes the stimulation of transcription factors such as the 
activation of the Jun NH2-terminal kinase (JNK) cascade or the transcription factor NF-κB (Nuclear 
factor kappa-light-chain-gene-enhancer of activated B cells). The RAC1-related activation of the NF-
κB pathway involves the production of reactive oxygen species (ROS), and initiates an anti-apoptotic 
transcriptional response, leading to an increased cyclin D1 expression and consequently promoting the 
cell cycle progression (Hinz et al., 1999; Joyce et al., 1999; Matos and Jordan, 2006).  
As already mentioned, compared to RAC1, RAC1b, shows a selective downstream signalling. 
Unlike RAC1, GTP-bound RAC1b ability to induce actin cytoskeleton reorganization is impaired – 
RAC1b is unable to induce lamellipodia formation. RAC1b is also unable to interact with two other 
well-established RAC1 signalling pathways, in particular, this splice variant is incapable to activate 
PAK1 effector and stimulate the JNK cascade (Matos et al., 2003; Fiegen et al., 2004; Singh et al., 
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2004). On the other hand, at least in the colorectal biological system, RAC1b retains the capacity to 
stimulate the NF-κB pathway, although its action is limited to the classical RelA-dependent NF-κB 
pathway, contrary to RAC1 that also stimulates the alternative pathway (RelB-dependent). The RAC1b 
stimulation of NF-κB classical pathway increases the cell cycle progression and cell survival, reducing 
the apoptotic rates (Matos and Jordan, 2005; Matos and Jordan, 2006). RAC1b was also shown to have 
the ability to mediate epithelial-mesenchymal transition (EMT) in breast (Radisky et al., 2005).  
 
 
Figure I.5. RAC1 and RAC1b signalling.  
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4.3. Association with cancer 
 
Malignant transformation is characterized by dramatic alterations in cell function and properties. 
This process includes the gain of migratory and invasive properties of tumour cells, increased 
proliferation levels and decreased apoptotic rates. RAC1 and RAC1b have been implicated in several of 
these cellular processes, namely in cell survival by increasing responses for apoptosis evasion and by 
stimulating cell cycle progression. The ability of these GTPases to interfere with these cellular functions 
could represent a tumorigenic property that allows the initiation of tumour formation, which, in turn, 
depends on the outcome of uncontrolled proliferation and anti-apoptotic mechanisms (Matos and Jordan, 
2005; Fritz and Kaina, 2006; Bid et al., 2013; Zhou et al., 2013).    
In agreement, a study using mouse mammary epithelial cells, reported that matrix metalloproteinase 
3 (MMP-3) induces RAC1b expression, which promotes an increase in cellular ROS (reactive oxygen 
species). EMT, oxidative damage to DNA and genomic instability are some of the consequences of ROS 
increased levels, which are ultimately involved in tumour formation, invasion and metastasis (Radisky 
et al., 2005).       
In fact, the elevated expression of RAC1b has been documented in colorectal (Jordan et al., 1999), 
breast (Schnelzer et al., 2000), lung (Zhou et al., 2013) and thyroid cancer (Silva et al., 2013). 
Specifically in colorectal carcinoma, the alternative splice variant of RAC1 was shown to functionally 
cooperate with BRAFV600E mutation to sustain the proliferation and survival of tumour cells (Matos et 
al., 2008). In a previous study, a group at IPOLFG (Silva et al., 2013) reported for the first time RAC1b 
expression in thyroid tissue.  Furthermore, the IPOLFG team shown that RAC1b is overexpressed in 
PTCs compared to normal thyroid tissue and that RAC1b overexpression is significantly associated with 
BRAFV600E mutation and poor clinical outcome in PTC. Similar to that reported in colorectal cancer, 
these findings point to an important role of RAC1b in PTC development, which may also be associated 
with a functional cooperation with BRAFV600E mutation.  
 
5. Signalling pathways involved in cancer  
 
The tumorigenesis process is often characterized by the accumulation of point mutations and 
changes in gene expression in pathways regulating specific aspects of cell proliferation and survival. 
Deregulation of some crucial pathways allows tumour cells to increase cell cycle progression, evade 
apoptosis and invade surrounding tissue.  Many of these pathways that regulate cellular processes are 
controlled by specific genes. Alterations in the sequence, expression or epigenetics of these genes can 
alter these signalling cascades, inducing modifications in the cellular processes. For example, alteration 
in TP53 gene (a gene involved in one of the major signalling pathways associated with apoptosis), 
induces alterations in this specific TP53 pathway, increasing tumour cells protection against apoptosis 
(Vogelstein and Kinzler, 2004).  
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In addition to TP53 pathway, there are many other signalling pathways described as being involved 
in the tumorigenic process of several tumours, such as JNK, PI3K, RTK (Receptor tyrosine kinases), 
cyclin D1 or NF-κB. NF-κB, in particular, was already implicated in several cancer types and has been 
studied as a potential therapeutic target (Debatin, 2004; Vogelstein and Kinzler, 2004; Dhillon et al., 
2007). 
 
5.1. NF-κB signalling pathway 
 
NF-κB (Nuclear factor kappa-light-chain-gene-enhancer of activated B cells) is a protein complex 
that plays a pivotal role in transcriptional control, cytokine production and in the regulation of several 
other cellular processes. In mammalian cells, the NF-κB family is composed of five members that form 
homodimers or heterodimers with each other – RelA (p65), RelB, c-Rel, p50 and p52. These proteins 
have an unique N-terminal Rel homology domain (approximately 300 amino acid) that allows dimer 
formation, binding to DNA and to NF-κB inhibitors (Karin and Ben-Neriah, 2000; Liang et al., 2004; 
Solt and May, 2008; Madonna et al., 2012). Conversely, the C-terminal domain differs between Rel 
(RelA, RelB and c-Rel) and NF-κB proteins (p50 and p52) – RelA, RelB and c-Rel exhibit 
transactivating function, while p50 and p52 contain inhibitory sequences associated to this C-terminal 
domain (Karin and Ben-Neriah, 2000; Madonna et al., 2012). The Rel homology domain also contains 
a nuclear localization signal (NLS) (Huang et al., 2000; Karin and Ben-Neriah, 2000; Karin et al., 2002). 
Unlike Rel proteins, p50 and p52 proteins are produced by proteolytic removal of C-terminal sequences 
of two inhibitory precursor proteins – NF-κB1/p105 and NF-κB2/p100, respectively. This removal 
allows the final proteins to enter the nucleus, usually as heterodimers with one of the Rel proteins that 
bears a transactivation domain (Karin et al., 2002; Bassères and Baldwin, 2006). 
The NF-κB dimers remain transcriptionally unstimulated as long as they are sequestered in the 
cytoplasmic compartment. In this form, NF-κB proteins are usually associated with members of the IκB 
family (consist of an N-terminal regulatory domain followed by a series of ankyrin repeats), such as 
IκBα, IκBβ, IκBε or the inhibitory precursor proteins – NF-κB1/p105 and NF-κB2/p100 (Bassères and 
Baldwin, 2006; Solt and May, 2008). Some studies indicated that IκB proteins act by masking the 
nuclear localization signal, which prevents the NF-κB dimers translocation into the nuclear compartment 
(Huang et al., 2000; Karin and Ben-Neriah, 2000).     
Their activation can happen as consequence of a diversity of stimuli, such as those activating 
membrane B cell receptors (BCR) or tumour necrosis factor receptors (TNFR). Moreover, several 
extracellular stimuli can also stimulate NF-κB pathway, namely inflammatory cytokines, viral and 
bacterial infections, oxidative and DNA-damaging agents, UV light and osmotic shock (Chen et al., 
2012; Karin et al., 2002).    
The regulation of the NF-κB dimers can be performed through two main pathways. Both signalling 
pathways that activate NF-κB transcriptional activity have as pivotal regulator, the IκB kinase (IκK - 
inhibitors of κB kinases) complex, which is composed by two catalytic subunits (IκKα and IκKβ) and a 
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non-catalytic regulatory subunit named NEMO (NF-κB essential modulator) or IκKγ. NEMO plays a 
crucial role in both pathways, whereas IκKβ is particularly important in the classical pathway and IκKα 
is also part of the non-canonical regulatory pathway. IκKs are involved in the phosphorylation of NF-
κB inhibitor proteins at specific serine residues (Liang et al., 2004; Waes, 2007; Solt and May, 2008; 
Sun, 2011).  
The first regulatory pathway (see Figure I.6), termed canonical or classical NF-κB activation 
pathway, applies to dimers composed by RelA, c-Rel and p50. It is usually triggered in response to 
microbial and viral infections and exposure to proinflammatory cytokines. The IκKβ has a particularly 
important role in this classical pathway by phosphorylating IκBα, which is subsequently ubiquitinated 
and degraded by the 26S proteasome. The degradation of NF-κB inhibitor, culminates with the 
accumulation of the dimeric NF-κB transcription factor (mostly composed by p50 and p65) into the 
nucleus, where it is able to bind κB site and induces the transcription of different target genes, most of 
them implicated in inflammation, survival and proliferation responses (Karin and Ben-Neriah, 2000; 
Karin et al., 2002). 
The second regulatory pathway (see Figure I.6), named non-canonical pathway, affects 
preferentially NF-κB2/p100 and RelB. The TNF (Tumour necrosis factor) cytokine family provides the 
most important stimuli for this pathway, which selectively activates the IκKα subunit along with another 
protein kinase called NIK (NF-κB inducing kinase). This activation induces a phosphorylation-
dependent proteolytic removal of C-terminal sequences of NF-κB2 inhibitory precursor protein, which 
allows RelB/p52 dimers to translocate to the nucleus and recognize specific kB sites in the promoter of 
target genes (Karin and Ben-Neriah, 2000; Karin et al., 2002; Sun, 2011). 
Each pathway have distinct regulatory functions, although some target genes are common to all NF-
κB proteins and are usually related to immunoregulatory and inflammatory processes, anti-apoptotic 
responses and cell cycle regulation (Shishodia and Aggarwal, 2002; Liang et al., 2004; Matos and 
Jordan, 2005).   
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Figure I.6. Canonical and non-canonical NF-κB activating pathways. 
 
 
5.1.1. Association with Tumorigenesis 
 
NF-κB plays three essential roles (Madonna et al., 2012). It is involved in the proinflammatory 
response, including immune, inflammatory and acute phase responses. It has already been established 
that this pathway sustains survival, maturation and recirculation of lymphocytes as well as T and B cell-
mediated immune responses (Liang et al., 2004). The ability to evade apoptosis is one of the most 
studied function of NF-κB pathway, which is known to induce the transcription of several anti-apoptotic 
proteins, such as Bcl-XL (B-cell lymphoma-extra-large), tumour necrosis factor receptor-associated 
factor 1 and 2 (TRAF1 and TRAF2, respectively), and the inhibitor-of-apoptosis (IAP) protein 1 and 2, 
which allows NF-κB to control the activity of the caspase family of enzymes (essential for the apoptotic 
cellular cascade) (Shishodia and Aggarwal, 2002; Liang et al., 2004; Solt an May, 2008; Madonna et 
al., 2012).  
Ultimately, NF-κB is involved in the regulation of cell cycle progression through its ability to induce 
the expression of cyclin D1 (Hinz et al., 1999; Joyce et al., 1999; Matos and Jordan, 2005). Cyclin D1 
works as a key sensor and integrator of extracellular signals of cells in G0 and early G1 phases, allowing 
the progression through the cell cycle, to S phase (Baldin et al., 1993; Stacey, 2003; Fu et al., 2004). 
Consequently, aberrant cyclin D1 expression is a critical event in cancer development that leads to 
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uncontrolled progression of cell cycle, usually induced by other cancer-related signals such as NF-κB 
activation or β-catenin (Hinz et al., 1999; Joyce et al., 1999; Fu et al., 2004; Liu et al., 2014).   
Given the extent of biological mechanisms associated with NF-κB pathways and the overlap of these 
mechanisms with some hallmarks of cancer, it is expectable to find deregulation of this pathway in 
association with several types of malignancies. Research work in this field documented several changes 
in the upstream pathways that lead to NF-κB activation to become deregulated in cancer (Staudt, 2010).   
Moreover, some studies reported that mutations which are usually associated with cancer initiation and 
development, such as RAS mutation, can lead to IκB inactivation and consequently to the upregulation 
of NF-κB pathway (Mizumoto et al., 2011; Chen et al., 2012).  
In fact, it has been reported over the years that increased activation of the NF-κB pathway is involved 
in some forms of cancer such as melanoma (Madonna et al., 2012), lung cancer (Chen et al., 2012), 
glioblastoma (Nogueira et al., 2011), colorectal cancer (Wang et al., 2009), thyroid cancer (Namba et 
al., 2007; Bauerle et al., 2010) and ovarian cancer (White et al., 2011).  
Given that, NF-κB pathway appears to have a crucial role in a vast diversity of tumours, the 
inhibition of this signalling cascade starts to be seen as a promising strategy for anti-cancer therapies.      
 
5.1.2. Association with RAC1b 
 
The ability of RAC1 to stimulate the NF-κB pathway is shared with its splice variant RAC1b, which 
was shown to be capable to promote IκB phosphorylation and nuclear translocation of RelA, in NIH 
3T3 mouse embryonic fibroblast cell line (Matos et al., 2003). Moreover, a study in colorectal cells 
demonstrated that RAC1b only stimulates the canonical NF-κB regulatory pathway, differing from 
RAC1 which is capable of stimulate both the classical and the alternative pathway. The activation of the 
non-canonical pathway by RAC1 could interfere, in a potential negative feedback regulation, with the 
RAC1-induced classical cascade. The selective RAC1b induction of the canonical regulatory pathway 
permits this GTPase to circumvent the negative feedback from the RelB pathway, which allows a 
continuously stimulation of the p50/RelA NF-κB-mediated transcription. Also in colorectal cells, the 
expression of RAC1b was shown to stimulate transcription from a luciferase reporter promoter 
containing consensus NF-κB binding sites, through a ROS dependent cascade (Matos and Jordan, 2006).  
In opposition, Singh and collaborators (2004) reported that RAC1b failed to activate the NF-κB 
transcription factor or stimulate cyclin D1 expression, in NIH 3T3 cell model (fibroblasts).  
Whether RAC1b contributes to NF-κB-mediated cellular processes (namely proliferation or 
apoptosis evasion) and to malignant progression in cell systems other than colorectal cancer remains to 
be clarified. 
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6. Follicular cell derived thyroid cancers, RAC1b and NF-κB 
pathway – a link to unravel  
 
Part 1. RAC1b role in FTC Tumorigenesis 
 
Our group has recently reported RAC1b expression in thyroid tissue (Silva et al, 2013). In fact, this 
variant was found to be overexpressed in PTCs compared to normal tissue, and to be associated with a 
subset of PTCs with a poor clinical outcome. These findings not only point to an important role of 
RAC1b in PTC development but also raise the possibility that RAC1b overexpression might be 
associated with other types of thyroid carcinoma, namely with other subtypes derived from follicular 
cells (non-medullary thyroid carcinomas). The second most frequent form of thyroid carcinomas is the 
FTC, representing about 15% of all cases. Despite the good prognosis usually associated to this type of 
malignancy, some patients present advanced tumours, non-responsive to radioiodine therapy.   
Hence, the broadening of the study of this GTPase to other follicular cells derived neoplasia, such 
as the FTCs, could provide novel information about the role of RAC1b in the thyroid tumorigenesis. 
This might as well contribute to the definition of prognostic biomarkers for this tumoural subtype, 
allowing an individual case management of risk level. 
On the other hand, since one major challenge in the clinical management of FTC patients is related 
with the inability to discriminate between benign and malignant follicular tumours at the preoperative 
stage, a comparative analysis of RAC1b expression between FTC and FTA may clarify the importance 
of this GTPase as a potential marker to be included in a broader panel of biomarkers to be used as 
diagnostic tool. 
  
Part 2. RAC1b - An activator of NF-κB pathway that contributes to thyroid Tumorigenesis? 
 
The potential association of RAC1b overexpression with PTC development, magnified the 
importance of investigating the molecular mechanisms associated with RAC1b overexpression and 
downstream signalling in thyroid tumorigenesis. In fact, the identification of precise alterations on 
signalling pathways associated with specific cancer processes would be pivotal for the understanding of 
molecular mechanisms behind tumour progression and for the development of diagnostic and prognostic 
biomarkers. In thyroid cancer there is, undoubtedly, the emerging need for a better understanding of the 
molecular events involved in the initiation and progression of malignancy as well as its association with 
failure in the response to iodine treatment and high recurrence rates. Understanding these mechanisms 
should contribute to individual case management optimization. 
A possible rational approach to investigate the molecular mechanisms associated with RAC1b 
overexpression and downstream signalling in thyroid tumorigenesis is to select a signalling pathway 
previously implicated in the tumorigenic process as a starting point. This selection was based in two 
previously published facts: NF-κB activation has been also reported to play an important role in thyroid 
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cancer (Namba et al., 2007; Bauerle et al., 2010); RAC1b selectively induces the canonical regulatory 
NF-κB pathway in colorectal cancer (Matos and Jordan, 2006). Hence, we considered relevant to study 
the role of RAC1b on NF-κB activation in thyroid tissue, and to further assess the effect of this potential 
RAC1b-mediated NF-κB stimulation in terms of cell growth and survival. Furthermore, given the role 
of Cyclin D1 as a cell cycle regulator, its association with some cancer events and the capacity of NF-
κB to induce cyclin D1 expression, it is reasonable to consider  Cyclin D1 as another target potentially 
affected by RAC1b overexpression.      
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II. OBJECTIVES 
 
We propose to analyse the expression of RAC1b in FTC and FTA, to compare the expression levels 
between the two groups (malignant versus benign) and correlate its expression with histopathological 
features and clinical outcome. This will allow us to evaluate RAC1b potential as a diagnostic/prognostic 
biomarker in FTC. 
We also intend to assess the RAC1b effect on NF-κB in thyroid cells to further understand whether 
RAC1b-mediated alteration of this pathway could interfere in cellular processes, such as cell cycle and 
apoptosis.  This will allow us to clarify the mechanisms involved in RAC1b-induced thyroid 
tumorigenesis.  
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III. MATERIALS AND METHODS 
  
1. Biological material – patients samples 
 
In the context of this thesis, samples representative of primary tumours from a cohort of 23 FTC 
patients (mean age of 54 years and Female: Male ratio 16:7) who underwent partial/total thyroidectomy 
at IPOLFG from 1994 to 2010, and 33 samples corresponding to FTAs were analysed. Samples were 
collected at surgery and immediately frozen and stored in liquid nitrogen. Tissue sample collection was 
carried out in accordance with protocols approved by the institutional review board and informed 
consent was obtained for the study together with the consent for surgery. 
 
2. DNA plasmids and constructs 
 
The plasmids used in this study are described in Matos and Jordan (2006) and Barros et al. (2009) 
and were a kind gift from Dr. Peter Jordan, from Instituto Nacional de Saúde Dr. Ricardo Jorge: 
pcDNA3-HA-IκBα(A32A36), -964-CycD1-Luc vector, 3x-kB-luc vector, pRL-TK reporter (a low 
level, constitutively expressed Renilla luciferase as internal control), pEGFP-RAC1b-L61, pEGFP-
RAC1-L61, pEGFP-RAC1b-WT, pEGFP-RAC1-WT. The pEGFP-C1 (BD Biosciences Clontech, 
USA) and the pcDNA3.1 (+)-empty vector (Invitrogen, USA) were used as negative controls.  
 
3. Cell Culture and transfection 
 
Two commercially available cell lines were used in this study – the K1 cell line which is derived 
from a primary human papillary thyroid carcinoma, and Nthy-ori 3-1 (Nthy) cell line derived from 
human thyroid follicular normal epithelium. 
Cells were maintained at 37°C in a humidified 5% CO2 environment. K1 cells grew in Dulbecco's 
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM: F12, 1:1) (Gibco, USA) containing 0,365 g/L 
of L-glutamine. Medium was supplemented with 10% (v/v) fetal bovine serum (FBS) (Biochrom, UK), 
1% (v/v) GlutaMax (Gibco, USA), 1,25% (v/v) sodium bicarbonate (Gibco, USA) and 0,5% (v/v) 
sodium pyruvate (Gibco, USA). Nthy cells were maintained in RPMI-1640 HEPES modified medium 
(Sigma, USA). Medium was supplemented with 10% (v/v) FBS and 1% (v/v) GlutaMax. When cells 
grow to an optimal confluence (80-100%), they were subcultured being detached by incubation with 1x 
trypsin-EDTA (Ethylenediamine tetraacetic acid) (Invitrogen, USA) at 37°C for approximately 1 minute 
(min), after a PBS 1x (Phosphate buffered saline) (Gibco, USA) washing step. 
Transfections were performed using the cationic lipid-based transfection reagent Lipofectamine 
2000 (Invitrogen, USA), according to manufacturer’s instructions. Briefly, 5x105 K1 cells or 2,5x105 
Nthy cells were seeded, 24 h before transfection, in 35 mm dishes (Nunclon, USA). Just before 
transfection, cells were fed with new fresh complete medium. Transfection was performed at 70-85% 
confluence. Plasmid DNA (2 μg) was diluted into 125 μL OPTI-MEM (Improved minimal essential 
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medium) (Gibco, USA); in an additional tube, 4 μL of transfection reagent was also diluted in 125 μL 
of OPTI-MEM and incubated 5 min at room temperature (RT). Diluted DNA and lipofectamine were 
then mixed gently and incubated for 20 min at RT to allow the formation of DNA-lipofectamine 
complexes. After incubation, 250 µL of transfection mixture was added to each culture dish.  
For luciferase reporter experiments, cells were co-transfected with either RAC1, RAC1b, or Mock 
control expression vectors, the specific reporters (1 µg), and the Renilla luciferase expression vector 
(0,1 µg). In all other experiments presented in this work, cells were transfected with RAC1/1b 
expression vectors and a pcDNA3.1 (+)-empty vector was used to adjust the total amount of transfected 
DNA to 2 µg. The amount of RAC1/1b vectors used was adjusted in order to achieve appropriate 
expression levels (see Table III.1). 
 
Table III.1. Description of plasmid amounts used in each assay, for each cell line. 
Assay 
Plasmid 
Luciferase reporter 
assay 
IFs 
(Immunofluorescence) 
Cell 
fractionation 
Total 
IκBα 
Cell 
death 
Cell 
cycle 
 K1 Nthy     
GFP-RAC1b-L61 1 µg 1 µg - 1 µg 1 µg 1 µg 1 µg 
GFP-RAC1-L61 0,3 µg 1 µg - - - - - 
pcDNA3.1 (+)- 
(Mock control) 
1 µg 1 µg - 1 µg 1 µg - - 
pEGFP- C1 
(Mock control) 
- - 1 µg - - 1 µg 1 µg 
GFP-RAC1b-WT 1 µg 1 µg 1 µg 1 µg 1 µg - 1 µg 
GFP-RAC1-WT 0,3 µg 1 µg 0,3 µg 0,3 µg - - - 
 
 
4. RNA extraction 
 
Total RNA extraction and purification were performed using the Rneasy Mini Kit (QIAGEN, 
Germany), according to the manufacturer’s protocol. An Eppendorf centrifuge 5417C (rotor radius = 95 
mm) were used during the procedures.  
RNA extraction from frozen tissue was performed using RLT lysis buffer with β-mercaptoethanol 
10% (v/v), after tissue fragmentation. Total RNA concentration was measured using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, USA), and frozen at -80°C. 
 
5. cDNA synthesis and amplification 
 
cDNA (complementary DNA) was synthetized from 2 μg of total RNA and reversely-transcribed 
using random primers (Roche, USA) and SuperScript II Reverse Transcriptase (Invitrogen, USA). In 
the first step, 2 µg RNA, 0,1 µL random primers (3 μg/μL), 0,4 μL deoxynucleotides (dNTPs, 25 μM) 
(GE Healthcare, UK) and bidestilled water (ddH2O) to a final volume of 12,9 μL were added. This first 
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reaction mixture was incubated at 65°C for 10 min (denaturation step) to remove RNA secondary 
structures that may hamper cDNA synthesis, and then cooled to 4°C. Then a second reaction mixture 
(7,1 μL) consisting in 4 μL first Strand Buffer 5x (Invitrogen, USA), 2 μL dithiothreitol (DTT, 0.1 M) 
(Invitrogen, USA), 1 μL Superscript II (200 U/μL) (Invitrogen, USA) and 0,1 μL RNAse OUT 
(Recombinant Ribonuclease Inhibitor, 40 U/μL) (Invitrogen, USA), was added. cDNA synthesis was 
performed in a T3000 thermocycler (Biometra, Germany), using the following basic program: 42°C for 
1 h (cDNA synthesis), 70°C for 15 min (inactivation) and 4°C (cooling) until the storage at -20°C.  
Using the synthesized cDNA, RT-PCR (Reverse transcription polymerase chain reaction) 
amplification was performed using primers for specific amplification of RAC1 and RAC1b. The primers 
(F-forward; R-reverse) for RAC1/1b amplification were RAC1/1bF (5’-atgttatggtagatggaaaaccg) and 
RAC1/1bR (5’-cggacattttcaaatgatgcagg), which generate PCR products of 154 and 211 base pairs, 
allowing the distinction between the two splice variants. The PCR reaction mix consisted of 25 µL PCR 
buffer 1x (home prepared by diluted 10 times a PCR buffer 10x in ddH20 and add 20 µL of each 100 
mM dNTP, see Appendix 1), 0.15 µL Taq DNA Polymerase (5 U/µl) (Invitrogen, USA), 0,5 µL reverse 
and forward primer (10 µM). 23 µL of this mixture was added to 2 µL cDNA to perform a total volume 
of 25 µL.        
Amplification reactions were performed in a T3000 thermocycler (Biometra, Germany), using a 
basic program described in Table III.2. 
 
Table III.2. RAC1/1b PCR amplification conditions. 
Stage Temperature (°C) Time Cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 30 seconds 35 
Annealing 621 30 seconds  
Elongation 72 30 seconds  
Final elongation 72 10 min 1 
Inactivation and 
cooling 
4 ∞ 1 
  1 Annealing temperature of RAC1/1b primers. 
 
The amplified PCR products were resolved by electrophoresis, on a 2% (w/v) agarose gel in TBE 
(Tris-borate-EDTA) buffer 1x (diluted from TBE buffer 10x, National diagnostics, USA), stained with 
0.05% (v/v) ethidium bromide (Invitrogen, USA). The visualization was performed under UV light and 
image acquired in BioDocAnalyse Transilluminator (Biometra, Germany).  
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6. Quantitative reverse transcription – PCR (qRT-PCR) 
 
The RAC1b and total RAC1 expression levels were quantified by qRT-PCR using TaqMan gene 
expression assay probes (Applied Biosystems, USA), accordingly to manufacturer’s instructions. Two 
different probes were used, one of them capable of selectively amplify RAC1b, and the other capable to 
amplify both RAC1 variants. 
To each sample, a reaction mixture was prepared with 1 µL TaqMan gene expression assay, 10 µL 
TaqMan gene expression Mastermix (Applied Biosystems, USA) and 5 µL ddH2O, in which 4 µL of 
diluted cDNAs (generally 1:20 in ddH2O) were added. Amplification reactions were performed in 
triplicate for each sample, on ABI Prism 7900HT Sequence Detection System (Applied Biosystems, 
USA). In order to evaluate the efficiency of each reactor used, successive dilutions of the same cDNA 
were analysed, enabling the assessment of the reaction efficiency for each detector. 
 
7. Luciferase reporter assays 
 
These assays are based on the fusion of a firefly luciferase gene with a putative promoter sequence, 
allowing the investigation of promoter activity by measuring the light output (luminescence) from 
luciferase enzyme that is expressed under the control of the promoter of interest. The luciferase activity 
was measured in Victor3 1420 Multilabel Counter Luminoter (Perkin Elmer, USA), using the Dual 
Luciferase Assay System (Promega, USA), according to the manufacturer’s protocol. In order to 
minimize errors and technical variability (distinct expression efficiencies or cell number by plate) it is 
recommended to use a second reporter gene constitutively active as internal control, in this case, the 
Renilla Luciferase. The two luciferases are measured sequentially (revised in Dual Luciferase Assay 
System technical manual – instructions for use of product, Promega, USA; Allard and Kopish, 2008). 
K1 and Nthy cells were seeded in 35 mm dishes and co-transfected with 100 ng of the pRL-TK 
(Renilla luciferase) reporter, 1 µg of NF-κB or cyclin D1 specific reporters and an optimized amount of 
RAC1/1b and Mock control constructs (see Table III.1). At 24 (NF-κB experiments) or 30 h (cyclin D1 
experiments) in the presence or absence of the RAC inhibitor EHT 1864, cells were scraped off and 
lysed with a passive lysis buffer 1x (PLB, Promega, USA) (specially formulated to minimize 
background auto-luminescence), following the manufacturer’s instructions. In EHT 1864 experiments, 
cells were incubated with the inhibitor (final concentration 0,1 mM) by 4 h. 
To 20 µL lysates, 50 µL Luciferase assay substrate (Promega, USA) was added and then the firefly 
luciferase activity was measured; the addition of 50 µL Stop&Glo reagent (Promega, USA) stopped the 
first reaction, which allows the measurement of Renilla luciferase activity. Firefly luciferase values were 
normalized to the internal control values and then a second normalization as -fold increase over the 
value of Mock control was performed. 
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Additionally, 20 µL lysate was collected for Western Blot analysis in order to assess protein 
expression levels.       
      
8. Confocal immunofluorescence microscopy 
 
K1 cells were grown on glass cover slips (10 by 10 mm), transfected with optimized amounts of 
RAC1b/RAC1 constructs and Mock control vector. Six hours after transfection, cells were subjected to 
starvation conditions (DMEM: F12 with 1% FBS) for 12 h. After this period, cells were stimulated with 
DMEM: F12 supplemented with 10% FBS for 30 min. Cells were then washed twice in PBS 1x and 
fixed with 4% (v/v) formaldehyde for 30 min at RT, following a permeabilization step with 0.2% (v/v) 
Triton X-100 in PBS for 10-15 min at RT. Cells were washed 3 times for 5 min in PBS-tween (0,05% 
[v/v]), and then incubated for 10 min at -20°C with methanol, following a 3 times PBS-tween wash step. 
Cells were incubated with the primary antibody anti-NF-κB p65 NLS (1:750) at 4°C, overnight, with 
shaking. After being washed 3 times in PBS-tween, cells were incubated for 1 h with Alexa Fluor 532 
goat anti-Rabbit IgG (Life Technologies, USA) (1:500). Coverslips were then washed 3 times in PBS-
tween, mounted in a mixture of VectaShield medium and VectaShield medium with DAPI (4',6-
diamidino-2-phenylindole) (Vector Laboratories, USA) (1:1), and sealed with nail polish. Images were 
recorded with the 405-nm, 488-nm, and 532-nm laser lines of a Leica TCS-SPE confocal microscope 
and processed with Adobe Photoshop software.  
 
9. Cell fractionation 
 
K1 cells were transfected with optimized amounts of RAC1b/RAC1 constructs and Mock control 
(see Table III.1). Six hours after transfection, cells were subjected to starvation conditions (DMEM: F12 
with 1% FBS) for 12 h. After that time, cells were stimulated with DMEM: F12 supplemented with 10% 
FBS for 30 min. 
Nuclear and cytosolic proteins were prepared using a previously described procedure (Solan et al., 
2002). Briefly, after a PBS 1x wash step, cells were scrapped off and lysed on ice in 150 µL cytosol 
fractionating buffer containing 50 mM HEPES (pH 7.2), 2 mM EDTA, 10 mM NaCl, 250 mM sucrose, 
2 mM DTT, 0.1% (v/v) Nonidet-P40 and a protease inhibitor cocktail (Sigma, USA). After 5 min on 
ice, the cytosolic fraction was harvested by centrifuging the lysate at 3000 g for 4 min and collecting 
120 µL supernatant, in which 30 µL 5x sample buffer (5x SB, see Appendix 1) were added. The remain 
pellet were resuspended in 300 µL cytosol fractionating buffer before a centrifugation (3000 g, 4 min, 
4°C). The nuclear proteins were extracted by resuspending the pellet in 35 µL of nuclei fractionating 
buffer composed by 50 mM HEPES (pH 7.2), 2 mM EDTA, 400 mM NaCl, 20% (v/v) glycerol, 2 mM 
DTT, and a protease inhibitor cocktail, for 20 min with occasional vortexing. After centrifugation 
(10000 g, 4 min, 4°C), the supernatant (nuclei proteins) was added to 8 µL 5x SB. An Eppendorf 
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centrifuge 5810R (rotor radius = 180 mm) were used during the procedures. Both fraction were analysed 
on Western Blot.      
    
10. Protein extraction with RIPA 
 
For the purpose of study total IκBα protein expression, K1 cells in 35 mm dishes were transfected 
with optimized amounts of RAC1b/RAC1 constructs and Mock control vector. At 24 h, cells were lysed 
in Radio-Immunoprecipitation Assay (RIPA) buffer (containing protease inhibitors, see Appendix 1). 
The lysates were centrifuged at 9000 rpm for 1 min in order to remove cell debris. For densitometry 
analysis, membranes images from three independent experiments were analysed using ImageJ software.  
 
11. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western Blotting 
 
Lysates resulting from luciferase reporter assays, cell fractionation experiments and protein 
extraction for total IκBα protein expression analysis, were prepared for Western Blot analysis: 5 µL of 
Sample buffer (5x SB, see Appendix 1) was added to each 20 µL of protein extract and these were boiled 
at 95°C for 10 min, in order to denature proteins. Equivalent amounts of total protein from each sample 
was loaded in 10 -12% SDS-PAGE gels (prepared accordingly to Sambrook and Russel, 2001; a 12% 
concentration were used in order to allow the distinction between RAC1 and RAC1b proteins). 
Electrophoresis was carried out at 0,02 Ampere per gel, for approximately 1 h 15 min. Proteins were 
then transferred to PVDF (polyvinylidene difluoride) membranes (Bio-Rad, USA) with a Mini Trans-
Blot Electrophoretic Transfer Cell (Bio-Rad, USA), at 70 Volt, 4°C, for 1 h. A 5% (w/v) non-fat milk 
in Tris Buffered Saline Buffer 0,05% Triton X-100 (TBST milk) solution were used to block non-
specific bindings to the membrane (1 h, RT), which were then incubated with specific primary antibodies 
(anti-RAC1, Millipore; anti-NF-κB p65 NLS, Thermo Scientific; anti-IκBα, Santa Cruz Biotechnology, 
USA) at appropriate dilutions (1:2000, 1:1000, 1:1000 respectively, in TBST milk), at 4°C, overnight, 
with shaking. Membrane were then incubated for 1 h at RT with secondary horse radish peroxidase-
conjugated antibody (anti-rabbit IgG and anti-mouse IgG, Thermo Scientific) diluted at 1:5000 in TBST 
milk. Band detection was performed using the ECL substrate (see Appendix 1) protocol in a ChemiDoc 
XRS System (Bio-Rad, USA) with Image Lab software. Membranes were then reprobed with anti-RAC1 
(1:2000), anti-β-actin (Sigma; 1:10000) and/or anti-Histone H2B (Millipore; 1:1000), used as loading 
controls.  
 
12. Cell death analysis by flow cytometry (FACS)  
 
The approach used in this work for cell death analysis by flow cytometry was based on the combined 
use of propidium iodide (PI, a fluorescent DNA intercalating dye) and Annexin V to determine if cells 
are viable, apoptotic (early or late stage), or necrotic. This distinction is based on differences in plasma 
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membrane integrity and permeability. Apoptotic stages are characterized by a loss of membrane 
integrity, which result in the exposure of phosphatidylserine (PS) to the extracellular environment, 
allowing Annexin V binding. On the other hand, PI is impermeant to live cells and early-stage apoptotic 
cells, while late stage apoptotic cells and necrotic cell stain positively, due to the passage of PI into the 
nucleus and consequent DNA binding (Annexin V Product Data Sheet, BioLegend, USA). 
K1 cells were seeded in 35 mm dishes and then transfected with optimized amounts of RAC1b-L61 
construct and Mock control vector. For IκBaa (non-degradable super-repressor) experiments, cells were 
co-transfected with 100 ng of pcDNA3-HA-IκBα (A32A36).  24 hours after transfection, cells were 
incubated in fresh medium in the absence or presence of staurosporine (Santa Cruz Biotechnology) at 
selected final concentrations (5 nM, 10 nM and 50 nM), for two more hours. After that time, cells were 
collected. 2 mL of the supernatant of each dish were collected into 15 mL tubes, following a PBS wash 
step. Cells were then trypsinized (200 µL per dish) and collected for the corresponding 15 mL tube. 
After centrifugation at 1200 rpm for 3 min (Eppendorf Centrifuge 5810R, rotor radius = 180 mm), 
supernatant were eliminated and cells were resuspended in 100 µL annexin V binding buffer (see 
Appendix 1). Cells were then stained with 2 µL propidium iodide (PI) (100 µg/mL) (Sigma, USA) and 
5 µL APC annexin V (15 µg/mL) (BioLegend, USA), and incubated at RT in dark, for 15 min. After 
incubation, cells were resuspended in 100 µL of annexin V binding buffer and analysed by flow 
cytometry (FACScalibur – Becton Dickinson). Cell acquisition parameters were defined using three 
blanks (with no stain, with PI alone, with annexin V alone), using the software BD Cell Quest. The 
acquired data was analysed in FlowJo (Tree Star Inc, USA) software.  
 
13. Cell Cycle analysis by flow cytometry (FACS) 
 
The methodology used in this context is based on the ability of staining the cellular DNA with a 
fluorescent DNA intercalating dye – PI – which binds the DNA, in cells permeabilized with ethanol, in 
a stoichiometric manner (the amount of stain is directly proportional to the amount of DNA within the 
cell). This stoichiometric binding allows the distinction between three cell cycle stages – G1 phase 
(corresponds to a gap before S phase, in which cell is preparing for DNA synthesis), S phase 
(characterized by DNA synthesis and duplication), G2/M phases (this two cell cycle phases cannot be 
identified individually; the G2 phase correspond to a gap after the S phase and before the cellular process 
of mitosis that happen in M phase) (Darzynkiewicz and Zhao, 2014).  
Like in cell death experiments, K1 cells were seeded in 35 mm dishes and then transfected with 
optimized amounts of RAC1b constructs and Mock control vector. For IκBaa (non-degradable super-
repressor) experiments, cells were also transfected with 100 ng of pcDNA3-HA-IκBα (A32A36).  Six 
hours after transfection, cells were exposed to starvation conditions (DMEM: F12 with 1%FBS) for 12h 
in order to allow cell cycle synchronization. After that time, cells were stimulated with DMEM: F12 
supplemented with 10% FBS for another six hours. After that time, cells were collected. The supernatant 
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was eliminated, following a PBS wash step. Cells were then trypsinized and collected for 1,5 mL tubes. 
After centrifugation at 1200 rpm for 3 min (Eppendorf Centrifuge 5417C; rotor radius = 95 mm), 
supernatant was eliminated and cells were resuspended 1 mL 70% (v/v) ethanol (Merck, Germany) and 
placed at 4°C, overnight, in order to fix cells and permeabilize the membrane (the minimal time for 
fixation and permebilization is 6 h). One day after, cells were centrifuged at 1200 rpm for 5 min, the 
supernatant was discarded and cells were then stained with 100 µL PI solution (50 µg/mL, see Appendix 
1) and incubated at 37°C in a water bath, for 40 min. After incubation, 1 mL of PBS 1x was added and 
cells were centrifuged at 1200 rpm, 4°C, for 10 minutes (Eppendorf Centrifuge 5810R, rotor radius = 
95 mm). Ultimately, supernatant was discarded and cells were resuspended in 250 µL of 0,2% (w/v) 
BSA (Bovine serum albumin) in PBS 1x and analysed by flow cytometry (FACScalibur – Becton 
Dickinson). The acquired data was analysed in FlowJo (Tree Star Inc, USA) software and the fraction 
of cells in each phase of cell cycle (G1, S, and G2/M) were evaluated.  
 
14. Statistical analysis 
 
Statistical analysis was carried out using GraphPad Prism 5 software (San Diego, USA). Whenever 
appropriate, values are expressed as mean ± SD (Standard deviation). The two-tailed Student’s t-test or 
two-tailed Fisher’s exact test and the paired two-tailed Student’s t-test were used to perform statistical 
analysis and evaluate statistical significance of results (accepted as p<0,05).    
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IV. RESULTS 
 
PART 1 
 
1. RAC1b is overexpressed in FTC  
 
RAC1b expression levels were assessed by qRT-PCR in 23 FTCs and 33 FTAs. RAC1b levels were 
firstly normalized to total RAC1 expression levels. The mean expression levels of RAC1b were 
significantly higher in FTCs (0,76 ± 0,94) compared to FTAs (0,34 ± 0,15) (p-value= 0,0152, two-tailed 
Student’s t-test). The mean fold increase was approximately 2,2. In order to discriminate FTCs and 
FTAs that overexpressed RAC1b from those that did not, we defined a threshold level of expression 
above which RAC1b were considered to be overexpressed. We set the threshold level at 0,76 (mean plus 
two standard deviations of the RAC1b expression level in a set of normal thyroid tissues). Based on 
these criteria, 7 out of 23 FTCs (30%) were found to overexpress RAC1b. Notably, in the FTAs group, 
no cases presenting RAC1b overexpression were found. Consistently, the difference in RAC1b 
overexpression between follicular adenomas and carcinomas was statistically significant (p-value= 
0,001, two-tailed Fisher’s exact test). 
 
2. RAC1b overexpression is associated with presence of distant 
metastasis and poorer clinical outcomes  
 
To investigate whether RAC1b overexpression was associated with histopathological parameters 
and clinical outcome, FTCs were grouped based on the clinical data available (see Table IV.3).  
  A comparison between FTC patients without distant metastasis (M0, 16 cases) versus FTC patients 
with distant metastasis (M1, 7 cases) disclosed a higher prevalence of RAC1b overexpression in M1 
group (5 out of 7 M1 cases). The association between RAC1b overexpression and presence of distant 
metastasis is statistically significant (p-value= 0,011). No other statistical significant correlation was 
found between RAC1b overexpression and histopathological features such as multifocality, vascular 
invasion, angioinvasion, Hürthle cell subtype or presence of poorly differentiated areas. 
FTCs were grouped based on the final clinical outcome. Group I (70% of patients) included patients 
who reached full sustained remission (no evidence of disease) and patients presenting biochemical 
evidence of disease. In contrast, group II (30% of patients) included patients with structural evidence of 
disease and those who died due to disease progression. The correlation between RAC1b overexpression 
and group II is statistically significant (p-value= 0,011), which further confirms that RAC1b is 
associated with poorer clinical outcomes in FTC patients.   
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Figure IV.7. RAC1b overexpression and its association with distant metastasis and clinical outcome. (A) 7 out of  23 
FTCs overexpressed RAC1b in opposition to none of the 33 FTA (p-value= 0,001). (B) The 23 FTCs were grouped according 
to presence of distant mestatasis: M0 – absecence of distant metastasis; M1 – presence of distant metastasis. The association 
between RAC1b overexpression and M1 group  is statistically significant (p-value= 0,011). (C) The 23 FTCs were grouped 
according to final outcome: group I –No evidence of disease (NED) and Biochemical evidence of disease (BED); group II - 
Structural evidence of disease (SED) and Death due to disease (D). The association between RAC1b overexpression and group 
II  is statistically significant (p-value= 0,0107). A two-tailed Fisher’s exact test were used to evaluate statistical significance of 
the associations. *p≤0.05 **p ≤0.01 ***p≤0.0001.     
 
 
 
 
 
 
 
 
A 
B 
C 
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Table IV.3. Clinical Data. 
 
ID, patient identification; M, male; F, female; HCC, Hürthle cells carcinoma; FTC, Follicular thyroid carcinoma; TNM, Tumour, node, metastasis staging; WI, widely invasive; EI, extrathyroidal 
invasion; M, Multifocal; A, angioinvasion; PD, poorly differentiated areas; 131I, number of 131I treatments; TT, Total thyroidectomy; HT, Hemithyroidectomy; TTC, Total thyroidectomy with 
cervical dissection; TG. Thyroglobulin; M1, Distant Metastasis; NED, No evidence of disease; BED, Biochemical evidence of disease; SED, Structural evidence of disease; D; Death due to 
disease; 
Patient  Histopathology  Treatment  Follow up  Clinical outcome  Molecular analysis 
ID Gender 
Age at 
diagnosis 
(years) 
 TNM Pattern WI/EI/M/A/PD  Surgery/
131
I  years 
last 
TG 
(ng/mL) 
anti 
TG 
M1  NED BED SED D Group 
 
RAS 
(K/N/H) 
RAC1b over-
expression 
1 F 68  T2NxMx HCC (-/-/-/+/-)  TT/1  5 <0,2 0 -   
   
I  (-/-/-) - 
2 F 45  T3NxMx HCC (-/-/-/+/-)  HT/0  8 1,7 nt -   
   
I  (-/-/-) - 
3 F 40  T3NxMx FTC (-/-/-/+/-)  HT/0  7 1,9 nt -   
   
I  (-/Q61R/-) - 
4 M 38  T3NxMx FTC (-/-/-/-/-)  TT/1  13 <0,2 0 -   
   
I  (-/-/-) - 
5 F 70  T3NxMx FTC (-/-/-/+/-)  TT/2  12 <0,2 0 -   
   
I  (-/-/-) - 
6 F 63  T3NxMx FTC (-/-/-/+/-)  TT/1  7 <0,2 0 -   
   
I  (-/-/-) - 
7 F 57  T2NxMx HCC (-/-/-/-/-)  HT/0  16 8,7 nt -   
   
I  (-/-/-) + 
8 F 59  T2NxMx FTC (-/-/-/-/-)  TT/1  15 <0,2 0 -   
   
I  (-/-/-) + 
9 M 38  T2NxMx FTC (-/-/-/-/-)  TT/1  11 <0,2 0 -   
   
I  (-/-/-) - 
10 F 39  T3NxMx FTC (+/-/-/+/+)  TT/2  9 <0,2 0 -   
   
I  (-/-/-) - 
11 F 34  T2NxMx HCC (-/-/-/-/-)  HT/0  7 11,1 nt -   
   
I  (-/-/-) - 
12 F 39  T2NxMx FTC (-/-/-/-/-)  TT/2  7 2,7 nt -  
 
 
  
I  (-/-/-) - 
13 F 81  T3NxMx HCC (-/+/-/-/-)  TT/1  4 <0,2 0 -   
   
I  (-/-/nt) - 
14 M 39  T3NxMx FTC (-/-/-/-/-)  TT/1  7 <0,2 0 -   
   
I  (-/-/-) - 
15 F 49  TxNxMx FTC (-/-/-/+/-)  HT/0  23 <0,2 0 -   
   
I  nt - 
16 F 65  T2NxMx FTC (-/-/-/+/-)  HT/0  6 <0,2 0 -   
   
I  (-/-/-) - 
17 F 71  T1NxM1 HCC (+/+/+/+/-)  TT/2  4 300000 0 
lung 
adrenal 
gland 
 
   
 
II  nt 
- 
18 F 42  T3NxMx HCC (-/-/-/+/+)  TT/6  10 2108 0 lung  
   
 II  (-/-/-) + 
19 M 58  T3NxM1 FTC (-/-/-/+/-)  TT/4  0 376 0 bone  
  
 
 
II  (-/Q61R/-) + 
20 M 53  T2NxMx HCC (+/-/+/+/-)  TT/4  7 632 0 lung  
   
 II  (-/-/-) + 
21 M 69  T2NxM1 FTC (-/-/-/+/-)  TT/5  2 4668 0 
bone, 
inguinal 
node  
 
   
 
II  (-/-/-) 
+ 
22 M 64  T4aN1bMx FTC (+/+/-/+/+)  TTC/3  2 28,6 0 lung  
  
 
 
II  (-/-/-) + 
23 F 87  T3NxMx FTC (+/+/-/+/-)  TT/5  10 43500 nt 
soft 
tissues 
 
  
 
 
II  (-/Q61L/-) - 
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PART 2 
 
 
3. RAC1b stimulates NF-κB in K1 cells  
 
In order to evaluate whether RAC1/1b overexpression influences the activation of the transcription 
factor NF-κB in thyroid biological systems, a luciferase reporter regulated by the canonical NF-κB-
consensus motif was tested in the human PTC derived cell line, K1, which does not present measurable 
RAC1b expression.  
Cells were transfected with pEGFP-RAC1b-L61, pEGFP-RAC1-L61, pEGFP-RAC1b-WT, 
pEGFP-RAC1-WT, or pcDNA3.1 (+)-empty vector (Mock control) in the presence of the NF-κB 
reporter. The effect of both RAC1/1b wild type forms and constitutively active mutants (L61) were 
measured and normalize to the Mock control.  Differences in NF-κB reporter levels induced by the 
RAC1 variants were observed: whereas RAC1b-L61 increased luciferase expression by 3,0-fold, RAC1-
L61 only induced a 1,6-fold increase. In agreement, also RAC1b-WT and RAC1-WT show different 
reporter induction capacities, being the first more effective (2,5- versus 1,9-fold increase, respectively). 
At least three independent experiments were performed and this differences were statistically significant 
(two-tailed Student’s t-test; see Figure IV.8, -A). To further confirm that RAC1/1b were responsible for 
the stimulation of NF-κB reporter, a RAC1/1b inhibitor was used (EHT 1864), to test whether a 
reversion on reporter activity was observed. In fact, we observed a decrease in NF-κB reporter activation 
when RAC1/1b activity was repressed. This decrease was statistically significant in three independent 
experiments (paired two-tailed Student’s t-test), for both RAC1b-L61/RAC1b-WT and RAC1-
L61/RAC1-WT (see Figure IV.8, -A). 
Transfection efficiency and overexpression of RAC1 variants was monitored by Western Blot (see 
Figure IV.8, -B) being the GFP-RAC1 and GFP-RAC1b proteins immunodetected as bands of 
approximately 48 KiloDalton (KDa) and 50 KDa, respectively. Detection of endogenous RAC1 was 
used as a loading control (approximately 21 KDa).   
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Figure IV.8. Luciferase activity of NF-κB regulated reporter in transfected K1 cells. (A) K1 cells were co-transfected 
with a luciferase reporter construct driven by the NF-κB consensus motif and with pEGFP-RAC1b-L61, pEGFP-RAC1-L61, 
pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or Mock control. (B) A Western Blot analysis was performed to monitor the 
expression levels of transfected GFP-RAC1/1b. Detection of endogenous RAC1 served as a loading control. Data are mean ± 
error bars (SD) of at least three independent experiments. p-values were calculated comparing the effect of RAC1/1b with the 
empty vector, using a two-tailed Student’s t-test. *p≤0.05 **p ≤0.01 ***p ≤0.001. A paired two-tailed Student’s t-test were 
used to evaluate the effect of EHT 1864 incubation compared to not treated cells. *p≤0.05 **p ≤0.01 ***p ≤0.001. 
 
 
4. RAC1b stimulates Cyclin D1 in the K1 cells 
 
We further studied the effect of RAC1b overexpression on Cyclin D1 (a downstream target for NF-
κB, which is involved in cell cycle regulation and associated with cancer development under specific 
conditions). For that, we measured the activity of a luciferase reporter driven by the cyclin D1 promoter 
in the PTC derived K1 cell line. Similarly to that described in NF-κB reporter assays, cells were 
transfected with pEGFP-RAC1b-L61, pEGFP-RAC1-L61, pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or 
pcDNA3.1 (+)-empty vector (Mock control), together with the luciferase reporters. As shown in Figure 
IV.9, -A, the cyclin D1 promoter was activated by the expression of both RAC1 and RAC1b, compared 
to Mock control, with the exception of RAC1-WT. Both RAC1-L61 and RAC1b-WT activate cyclin D1 
promoter to the same extent (1,2- fold increase), whereas RAC1b-L61-induced activation was much 
higher (1,8-fold increase), with a statistically highly significant difference in at least three independent 
experiments. Using, the RAC1 inhibitor EHT 1864, it was possible to observe a reversion on luciferase 
activity, indicating that cyclin D1 promoter activity decreases when RAC1/1b action is repressed and 
confirming RAC1/1b regulation of cyclin D1 pathway. Although the obvious reduction on reporter 
activity levels in cells incubated with EHT 1864, compared to cell not subjected to EHT 1864 action 
(3,0-; 1,4-; 1,1- and 1,4-fold decrease for RAC1b-L61, RAC1b WT, RAC1-L61 and RAC1-WT, 
Blot Anti-Rac1 
GFP-RAC1b 
GFP-RAC1 
 
 
Endogenous RAC1 
 
A 
B 
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respectively), just one experiment was performed and, consequently, we were not able to evaluate the 
statistical significance of this results (see Figure IV.9, -A). 
The immunodetection by Western Blot allowed us to confirm the overexpression of all the 
transfected proteins. Detection of endogenous RAC1 was used as a loading control (see Figure IV.9, -
B).   
 
 
 
 
Figure IV.9. Luciferase activity of cyclin D1 regulated reporter in transfected K1 cells. (A) K1 cells were co-transfected 
with a luciferase reporter construct driven by the cyclin D1 promoter and with pEGFP-RAC1b-L61, pEGFP-RAC1-L61, 
pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or Mock control. (B) The immunodetection by Western Blot confirmed the 
expression of transfected GFP-RAC1/1b. Detection of endogenous RAC1 served as a loading control. Data are mean ± error 
bars (SD) of at least three independent experiments, with the exception of EHT 1864 experiment, which just one was performed. 
p-values were calculated comparing the effect of RAC1/1b with the Mock control, using a two-tailed Student’s t-test. *p≤0.05 
**p ≤0.01 ***p ≤0.001.  
 
 
5. RAC1b stimulates p65 translocation to the nucleus  
 
In order to address RAC1b mediated activation of the transcription factor NF-κB in situ, we first 
study the effect of RAC1b overexpression on the subcellular localization of p65 protein (RelA) in our 
PTC derived cell model. For that, we used an antibody that specifically binds the NLS (nuclear 
localization signal) region on N-terminal Rel homology domain of p65 protein (approximately 60 KDa). 
This protein is involved in the canonical NF-κB regulatory pathway and it is able to form p50/p65- 
heterodimers. IκBα is capable to interact with p65 dimers and inactivates their transcriptional potential 
by masking the NLS, trapping these dimers into the cytoplasmic compartment. When the NF-κB dimers 
are activated, the IκBα is marked to degradation which exposes the NLS region, allowing the nuclear 
translocation and DNA binding. To assess p65 nuclear translocation, we used an antibody that binds the 
Blot Anti-Rac1 
GFP-RAC1b 
GFP-RAC1 
 
 
Endogenous RAC1 
 
A 
B 
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uncovered NLS region of p65, i.e. the active p65 dimers. We addressed p65 subcellular localization by 
two methodologies– immunofluorescence microscopy and cell fractionation.  
For immunofluorescence experiments, K1 cells were transfected with pEGFP-RAC1b-WT, pEGFP-
RAC1-WT, or pEGFP- C1 (Mock control). The discrimination between transfected and non-transfected 
cells was possible due GFP fluorescence signal (green). Nuclei were counterstained with DAPI (blue). 
Additionally, cells were immunostained with Anti-p65 NLS (red). As shown in Figure IV.10, -A, red 
signal was more intense on cells transfected with RAC1b compared to that transfected with only GFP, 
indicating higher levels of active p65. Moreover, cells transfected with RAC1b-WT revealed a clear 
nuclear localization of p65, compared to non-transfected or to GFP vector transfected cells. In contrast, 
RAC1-WT had little effect on the accumulation of p65 in the nucleus, and the red signal intensity was 
slightly higher than that observed in GFP vector transfected cells, suggesting a modest effect of RAC1-
WT on p65 dimers activation. These results are in agreement with the higher stimulation of the NF-κB 
controlled reporter that we have previously observed for RAC1b.  
An additional set of assays with the NF-κB luciferase reporter was performed in parallel with 
immunofluorescence experiments, in which cells were submitted to the exact same experimental 
conditions, using a pcDNA3.1 (+)-empty vector as negative control (Mock). As we can see in Figure 
IV.10, -B, an activation of NF-κB promoter was observed in cells transfected with RAC1b-WT 
(statistically significant difference compared to Mock control), in opposition with RAC1-WT which 
showed no effect. These results are consistent with the immufluorescence data. 
 
- 38 - 
 
 
 
 
 
Figure IV.10. RAC1b overexpression affects subcellular 
location of p65-NLS protein. (A) K1 cells were transfected with 
pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or Mock control. Cells 
were submitted to starvation conditions, and stimulated with higher 
FBS levels before fixation. Nuclei were counterstained with DAPI, 
and fluorescent signals were recorded by confocal microscopy. The 
overlay image of the DAPI, GFP and Red channels is shown. (B) 
Luciferase activity of NF-κB regulated reporter was measured in 
K1 cells submitted to the exact same conditions that cells analyse 
by immunofluorescence. Data are mean ± error bars (SD) of four 
independent experiments. p-values were calculated comparing the 
effect of RAC1/1b with the Mock control, using a two-tailed 
Student’s t-test. *p≤0.05 **p ≤0.01 ***p ≤0.001. 
A 
B 
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To further confirm the data obtained with the immufluorescence microscopy approach, we assessed 
the effect of RAC1b on the subcellular localization of p65 protein by subcellular fractionation 
experiments.  K1 cells were transfected with pEGFP-RAC1b-L61, pEGFP-RAC1b-WT, pEGFP- 
RAC1-WT, or pcDNA3.1 (+)-empty vector (Mock control). As we can see on Figure IV.10.1, in cells 
transfected with RAC1b-L61 and RAC1b-WT we observed an increase on p65-NLS protein expression 
in the nuclear fraction, compared to Mock control.  These data indicate that RAC1b expression activates 
p65 dimers in higher extent than RAC1-WT or Mock control, inducing nuclear translocation.  
Transfection of RAC1/1b variants was monitored by Western Blot. Histone H2B (approximately 
15KDa) and β-Actin were used as a markers of nuclear and cytoplasmic fractions, respectively. 
Although this analysis revealed some cross-contamination between nuclear and cytoplasmic fractions, 
marker’s expression was similar in all samples. This allows us to consider these results as an indicative 
that RAC1b induces p65 activation and nuclear translocation, which is in agreement with the results of 
NF-κB reporter experiments. Altogether, these data reinforce the ability of RAC1b to activate the NF-
κB canonical pathway, inducing the translocation of p65 dimers into the nucleus.   
 
 
6. RAC1b induces a decrease in total IκBα protein expression  
 
To further confirm the RAC1b impact on the activation of the canonical NF-κB pathway, we study 
the influence of RAC1b on total IκBα protein expression (a negative regulator in the canonical NF-κB 
pathway). K1 cells were transfected with pEGFP-RAC1b-L61, pEGFP-RAC1b-WT, or pcDNA3.1 (+)-
empty vector (Mock control). Levels of total IκBα were assessed by Western Blot (see Figure IV.11, -
A) and posteriorly analyse by densiometry using ImageJ software (see Figure IV.11, -B).  These levels 
 Cytoplasmic Fraction Nuclear Fraction 
 
Anti-p65 
NLS   
1 – GFP-RAC1b-L61 
2 –  GFP -RAC1b-WT 
3 – GFP-RAC1-WT 
4 – Mock control 
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Anti-β-Actin  
  
Anti- 
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Figure IV.10.1. RAC1b overexpression affects subcellular location of p65-NLS protein.  K1 cells were transfected with 
pEGFP-RAC1b-L61, pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or Mock control. Cells were submitted to starvation conditions, 
and stimulated with higher FBS levels before the lysis process. A cell fractionation protocol were use so that a nuclear and a 
cytoplasmic fraction was obtained. A Western Blot analysis of these fractions were performed. Histone H2B was detected as a 
marker for nuclear proteins fraction, and β-Actin was detected as a marker for cytoplasmic fraction.   
1         2           3          4    1         2           3          4    
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were first normalize to β-actin (used as endogenous control) and then normalized to Mock control. As 
shown in Figure IV.11, both RAC1b-L61 and RAC1b-WT induced a decreased in total IκBα levels, 
compared to the Mock control. These decreases were statistically significant. 
Since IκBα is a potent inhibitor of p50-p65 dimers, the decreased levels of this protein in the cell is 
likely related to higher activation levels of NF-κB transcription factor. These data corroborate the effect 
of RAC1b overexpression in the stimulation of the canonical NF-κB pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.11. Total IκBα protein levels in K1 cells assessed by western-blotting. (A) K1 cells were transfected 
with pEGFP-RAC1b-L61, pEGFP-RAC1b-WT, or Mock control. IκBα protein levels were analysed by Western Blot. RAC1 
analysis by Western Blot were performed to monitor expression levels of transfected GFP-RAC1b. Detection of endogenous 
RAC1 can also serve as a loading control. (B) Protein levels were analysed by densiometry using ImageJ software. These levels 
were first normalized to β-actin (≈ 42KDa), and then normalized to Mock control. p-values were calculated comparing the 
effect of RAC1b with the Mock control, using a two-tailed Student’s t-test. *p≤0.05 **p ≤0.01 ***p ≤0.001.  
 
 
7. RAC1b protects cells against apoptosis induced by staurosporine 
 
In this work, we were also able to gain some insights into how RAC1b-induced NF-κB activation 
in thyroid cells modify cellular processes related to tumour development such as apoptosis. K1 cells 
were transfected with pEGFP-RAC1b-L61 or pEGFP-C1 (Mock control). Then, cells were subjected to 
different concentrations of staurosporine, a compound that induces apoptotic cell death (Belmokhtar et 
al., 2001).  
The data acquired in FACScalibur was processed using the FlowJo software so that only transfected 
cells were considered for analysis and quantification of the levels of apoptosis – the distinction between 
transfected and non-transfected cells was possible due GFP signal also detected by FACScalibur. The 
results were normalized to Mock, RAC1b-L61 and RAC1b-L61 plus IκBaa controls without 
staurosporine, respectively. As shown on Figure IV.12, we observed an increase in apoptosis when cells 
were treated with increasing amounts of staurosporine, with the exception of cells transfected with 
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RAC1b-L61, for which staurosporine was not able to induce apoptosis. It is important to highlight the 
decrease on apoptosis observed in cells transfected with RAC1b, compared to Mock control (1,9-fold 
decrease, for 5 nM staurosporine), for the same staurosporine concentrations. Nevertheless, this decrease 
was only statistically significant for the lowest concentration of staurosporine (5 nM) (see Figure IV.12). 
Moreover, in cells expressing the IκBaa super-repressor (the mutated non-degradable IκBαA32A36) 
which traps the p50/p65 dimers on the inactive form, we were able to observe a reversion of the effect 
of RAC1b on apoptosis inhibition, indicating that this effect is NF-κB-dependent. 
Altogether, these data suggest that RAC1b is able to protect cells against apoptosis induced by 
staurosporine, in a process involving the NF-κB pathway. Nevertheless, further assays are needed to 
confirm and increase the statistical significance of these results. 
 
 
Figure IV.12. Apoptosis analyzes by flow cytometry (Annexin V and PI staining). K1 cells were transfected with 
pEGFP-RAC1b-L61, or Mock control. For study if RAC1b effect was influenced by the NF-κB canonical pathway, cells were 
also transfected with pcDNA3-HA-IκBα (A32A36). The percentage of total apoptosis (early and late stages) was normalize to 
Mock, RAC1b-L61 and RAC1b-L61+IκBaa controls, without staurosporine.  Data are means ± error bars (SD) of four 
individual experiments. p-values were calculated comparing the effect of RAC1b with the Mock control, using a two-tailed 
Student’s t-test. *p≤0.05 **p ≤0.01 ***p ≤0.001. 
 
 
8. RAC1b stimulates cell cycle progression 
 
In view of the effect of RAC1b overexpression on cyclin D1 promoter observed in luciferase 
reporter assays, we decided to analyse RAC1b effect on cell cycle progression, by flow cytometry. K1 
cells were transfected with pEGFP-RAC1b-L61, pEGFP-RAC1b-WT or pEGFP-C1 vector (Mock 
control).  Only transfected cells were considered in the present analysis. As shown in Figure IV.13, 
RAC1b-L61 was able to increase the proportion of cells in the S and G2 phases, compared to the Mock 
control (phase S: 12,0% and 9,9%, respectively; phase G2: 13,6% and 10,2%, respectively), indicating 
a progression in cell cycle. Also RAC1b-WT was able to increase the proportion of cells in the S phase, 
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compared to the Mock control (13,3% and 9,9%, respectively). Lower percentage of cells transfected 
with RAC1b-WT were found in G2 phase, compared to RAC1b-L61 (7,2% and 13,6% respectively).  
Moreover, in cells co-transfected with the IκBaa super-repressor we observed a reversion on the RAC1b-
L61 effect. These data led us to hypothesize that RAC1b-L61 is able to induce cell cycle progression 
and increase proliferative activity, in a process involving the NF-κB pathway. Wild type RAC1b also 
induced cell progression from G1 phase to S phase although its effect on cell cycle progression (S and 
G2/M phases) was not obviously reversed by the IκBaa super-repressor. Only two experiments were 
performed, so further assays are needed to confirm these results and increase its statistical significance. 
 
  
Figure 13. Cell cycle analyzes by flow cytometric (PI staining). K1 cells were transfected with pEGFP-RAC1b-L61, 
pEGFP-RAC1b-WT, or Mock control. To study whether RAC1b effect was related to NF-κB, cells were co-transfected with 
pcDNA3-HA-IκBα (A32A36). The percentage of cell in each phase of cell cycle is represented. Data are means ± error bars 
(SD) of two individual experiments.  
 
9. RAC1b effect on Nthy cell line 
 
In order to address whether the effect of RAC1b overexpression on NF-κB pathway is present in 
thyroid biological systems other than the K1 PTC derived cell line, we evaluated this effect on the human 
normal follicular thyroid epithelium derived cell line, Nthy. Cells were transfected with pEGFP-RAC1b-
L61, pEGFP-RAC1-L61, pEGFP-RAC1b-WT, pEGFP-RAC1-WT, pcDNA3.1 (+)-empty vector (Mock 
control). We use the luciferase reporter systems for NF-κB and cyclin D1 as described above for K1 
cells.  
Cell Cycle Analysis 
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The effect of RAC1 and RAC1b was measured and normalized to the Mock control. Both RAC1 
and RAC1b, either the WT or the active dominant L61, induced a statistically significant increase in the 
activity of NF-κB reporter (results shown in Figure IV.14, -A). Notably, in this system, the effect of 
RAC1 was remarkably more pronounced compared to its splice variant RAC1b: 10,0- versus 2,3- fold 
increase for active dominants; 2,3- versus 1,8- fold increase for WT forms, respectively. Results 
obtained in Nthy confirm the ability of RAC1b to induce NF-κB reporter activity, similar to that found 
in K1 cells. Nevertheless in this cell type, RAC1 has found to have a considerable more intense effect 
on NF-κB reporter activation than that observed for RAC1b.  
We also evaluate the effect of both variants in the activation of cyclin D1 promoter activity. Both 
RAC1 and RAC1b were shown to increase the promoter activity, compared to the Mock control (see 
Figure IV.14, -C). Compared to K1, the extent of this effect was lower and only RAC1 was able to 
induce a statistically significant increase (2,8- and 1,6- fold increase for L61 and WT form of RAC1, 
respectively).  RAC1b induced a 1,4- (L61) and 1,3- (WT) fold increase in cyclin D1 promoter activity. 
A Western Blot analysis was performed to monitor the expression levels of transfected GFP-
RAC1/1b proteins (Figure IV.14, -B-D).   
Unfortunately we were unable to go further on this study due to time constraints. Nevertheless the 
data obtained are consistent with the effect of RAC1b overexpression on the stimulation of NF-κB 
pathway, being this effect also able to occur in a thyroid cell system derived from normal tissue. 
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Figure IV.14. Luciferase activity of NF-κB and cyclin D1 regulated reporter in transfected Nthy cells. Nthy cells were 
co-transfected with a luciferase reporter construct driven by the NF-κB consensus motif (A) or driven by the cyclin D1 promoter 
(B) and with pEGFP-RAC1b-L61, pEGFP-RAC1-L61, pEGFP-RAC1b-WT, pEGFP-RAC1-WT, or Mock control. (B, D) A 
Western Blot analysis were performed to monitor expression levels of transfected GFP-RAC1/1b. Detection of endogenous 
RAC1 served as a loading control. Data are mean ± error bars (SD) of at least three independent experiments. p-values were 
calculated comparing the effect of RAC1/1b with the Mock control, using a two-tailed Student’s t-test. *p≤0.05 **p ≤0.01 
***p ≤0.001.  
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V. DISCUSSION 
 
Cancer is a disease that may arise from all different types of cell in the body, resulting from abnormal 
proliferation of these cells (Cooper, G., 2000). After years of rapid advances, cancer research has defined 
a group of underlying principles that are shared by all cancers – hallmarks of cancer (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011). Nevertheless, there are colossal differences between 
different types of cancer in terms of biological and molecular behaviour. Moreover, phenotypic and 
functional heterogeneity can arise among cancer cells within the same tumour (Cooper, G., 2000; 
Meacham and Morrison; 2013). During many years, the clinical behaviour of human cancer has been 
predicted based on histological features. However, different biological evolution and clinical responses 
were observed for the same histological type of tumours (Liotta and Petricoin, 2000).  
The pursuit for new ways to characterize each tumour as a particular entity, tailoring case 
management to individual risk level, has been persistent. One widely used approach is related to genetic 
alterations linked to several types of cancer. Genetic analysis has been performed in order to study how 
mutations identified in cancer-critical genes can affected crucial pathways, and consequently modify 
tumour cell properties and behaviour (Alberts et al., 2002). Several proteins have also been associated 
with cancer development, namely Rho-family proteins, interfering with cancer-related pathways and 
cellular features (Sahai and Marshall, 2002). 
Recent findings of our group point to an important role of RAC1b, a small GTPase belonging to 
Rho-family, in PTC development and definition of poor clinical outcomes (Silva et al., 2013). This 
finding made us to consider the hypothesis that RAC1b may be involved in tumorigenesis of other 
thyroid tumour subtypes, namely in other tumours derived from follicular cells besides PTCs. One major 
finding in this thesis work is that RAC1b is overexpressed in FTCs (30%) compared to FTAs (0%), 
being this difference statistically significant. We also found a striking correlation between poorer clinical 
outcome or the presence of distant metastasis and RAC1b overexpression (p= 0,01 for both associations). 
Altogether, these data suggest that RAC1b is involved in FTC development, similar to that previously 
found in PTCs. Further validation is needed to confirm the potential of this GTPase as a biomarker of 
clinical outcome for FTC patients.  
Moreover, the dissimilarity found in RAC1b overexpression between FTCs and FTAs strengthens 
the potential of RAC1b as a marker for discrimination between benign and malignant follicular lesions. 
In fact, the distinction between benign and malignant tumours continues to be an important issue in 
cancer pathology (Cooper, 2000). In thyroid follicular neoplasia, this problem earns bigger proportions 
since surgery is the only reliable way to distinguish FTCs from FTAs. Many studies have been 
performed in order to find pre-surgical discrimination markers.  HMGA2 and hTETR, for instance, 
despite being differential expressed between FTCs and FTAs, were shown not to be consistently able to 
differentiate benign from malignant lesions (Nagar et al., 2014.)   Also, RAC1b may not be used as a 
single marker of discrimination, because of its low sensitivity levels (only 30% of FTCs were found to 
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overexpress RAC1b). Nevertheless, we can conceive that it might potentially incorporate a more 
extensive panel of biomarkers, allowing the distinction from benign vs. malignant thyroid lesions with 
reliable sensitivity and specificity levels, in a preoperative stage. The optimal outcome would be a long 
term adaptation in standard therapy, in which surgery would only be necessary for confirmed FTC cases.  
In a previous study of our group, it was shown that RAC1b is expressed in thyroid tissue and that is 
overexpressed in a subset of PTCs associated with poorer outcomes. Nevertheless, the molecular 
pathways through which this GTPase participates in thyroid tumorigenesis requires further 
investigation. In this thesis project, we proposed the investigation of the molecular mechanisms 
associated with RAC1b overexpression and downstream signalling in thyroid tumorigenesis. High-
throughput screening methodologies are presently the state of the art approaches for providing starting 
points about gene expression changes that could be associated with cancer development, as well as the 
signalling pathways implicated (Alberts et al., 2002; Gombos et al., 2007). However, there are some 
signalling pathways reported to be involved in several types of tumours, such as p53, JNK, PI3K, RTK, 
cyclin D1 or NF-κB – the “usual suspects” to be involved in cancer development – that may be worth 
considering (Debatin, 2004; Dhillon et al., 2007).  
In this project, we choose to study the transcription factor NF-κB, which seems to be implicated in 
several types of cancer. The activation of this transcription factor by RAC1 signalling has been 
documented over the years and this activation process seems to involve ROS production, and promote 
tumorigenesis by increasing the expression of cyclin D1 (Hinz et al., 1999; Joyce et al., 1999; Matos 
and Jordan, 2006), matrix metalloproteinases (Kheradmand et al., 1998) and anti-apoptotic genes (Karin 
et al., 2002; Shishodia and Aggarwal, 2002). Back to 2006, RAC1b was also shown to be a potent 
activator of NF-κB canonical pathway in colorectal cancer biological system (Matos and Jordan, 2006). 
However, whether the RAC1b-mediated activation of NF-κB is relevant in thyroid cancer remained to 
be determined. 
Another important finding in this work is that RAC1b overexpression is able to induce the activation 
of the canonical NF-κB activating pathway and cyclin D1 in thyroid biological system. Also, the 
activation of this pathway in thyroid seems to have implications on the regulation of crucial cellular 
processes such as apoptosis and cell cycle progression. The effect, described here in thyroid, of RAC1/1b 
on the activation of the NF-κB canonical pathway and cyclin D1 transcription is consistent with data 
reported by Matos and Jordan (2006) in colorectal cancer, demonstrating the role of RAC1b as a potent 
activator of NF-κB pathway. However, while in colorectal cancer both RAC1 and RAC1b stimulate the 
cyclin D1 reporter to an equivalent extent and RAC1 appeared to be more effective than RAC1b in 
activating the NF-κB reporter, in the cell line derived from a human papillary thyroid carcinoma (K1) 
RAC1b was shown to induce a substantially greater effect than RAC1. These results point to differences 
in the RAC1 and RAC1b mechanism of regulation between thyroid cancer cells and colorectal cancer 
cells. Likewise, differences in these same mechanisms were also observed between thyroid cancer cells 
and cells derived from human normal follicular thyroid epithelium (Nthy).  
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In order to further confirm RAC1/1b-mediated activation of NF-κB transcription factor, considering 
the canonical regulatory pathway in particular, we evaluated the subcellular localization of p65 – a Rel 
protein involved in the canonical pathway. We detected higher levels of active p65 and a clear nuclear 
localization of this protein in cells transfected with RAC1b-WT compared to the Mock control. These 
data corroborate the effect of RAC1b on the activation of NF-κB canonical pathway, since P50-p65 
dimers, are only capable to enter the nucleus when they are on the active state (Karin and Ben-Neriah, 
2000; Karin et al., 2002). Additionally, we evaluated the effect of RAC1b expression on the levels of 
endogenous IκBα, a NF-κB inhibitor with a crucial role in the canonical pathway regulation. Our results 
show that the endogenous IκBα protein levels were halved by both wild type and constitutively active 
RAC1b. These data are in agreement with Matos and Jordan (2006) results that showed a RAC1b-
induced decrease on endogenous IκBα levels on colorectal cancer.  
Then, we aimed to address the consequences of the RAC1b-induced NF-κB activation on thyroid 
cellular processes. The capacity of NF-κB to block TNF-induced apoptosis has been shown many years 
ago (Liu et al., 1996). Actually, the anti-apoptotic effect of NF-κB is well accepted, which could protect 
cells from various apoptotic agents. The NF-κB transcription factor promotes cell survival by either 
inducing the transcription of anti-apoptotic genes or downregulating the activity of apoptotic genes 
(Karin et al., 2002; Shishodia and Aggarwal, 2002). This supports our data showing a RAC1b-induced 
protection against the effect of staurosporine, a strong inducer of apoptosis in many different cell types, 
through a mechanism mediated by NF-κB transcription factor. 
In this thesis work we demonstrated the ability of RAC1/1b to activate cyclin D1 reporter activity. 
Given the role of cyclin D1 as a key regulator of cell cycle (Baldin et al., 1993; Stacey, 2003; Fu et al., 
2004), we decided to evaluate the effect of RAC1b in cell cycle progression in thyroid cells. Our results 
indicated that RAC1b-L61 induced a cell cycle progression through a mechanism influenced by NF-κB 
transcription factor, which is supported by evidences that cyclin D1 can be induced by NF-κB activation 
(Hinz et al., 1999; Joyce et al., 1999; Fu et al., 2004). Also RAC1b-WT seems to stimulate NF-κB-
mediated G1/S progression, which enhances the RAC1b ability to act as a pro-proliferative signal. The 
ability of RAC1b, both the wild type and the constitutively active mutant, induce G1/S progression is in 
agreement with Matos and Jordan (2005) findings that show RAC1b expression to be sufficient to 
stimulate G1/S progression via the activation of NF-κB. Furthermore, the lower percentage of cells 
transfected with RAC1b-WT found in G2 phase, compared to RAC1b-L61, is in agreement with the 
data obtained in reporter assays, in which RAC1b-L61 revealed to induce a higher increase in cyclin D1 
promoter activity, compared to RAC1b-WT, since at G2 phase cyclin D1 levels are usually elevated 
(Stacey, 2003; Yang, 2006).  
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VI. CONCLUSION 
 
In this thesis work, we tried to clarify the role of RAC1b in follicular cell derived thyroid 
tumorigenesis and progression. Our finding about the association of RAC1b overexpression with a worse 
prognosis and presence of distant metastases in FTC patients emphasizes the role of this GTPase as a 
prognostic marker for follicular cell derived thyroid cancers.  
Our data supports the potential of RAC1b to be incorporated into a wide panel of biomarkers, which 
could have important implications in the diagnosis of follicular thyroid carcinoma, and help to 
circumvent the problem of discrimination between FTCs and FTAs. 
Given the particular features of each tumour, the clarification of the molecular mechanisms behind 
neoplasia development and progression can be pivotal. Many genetic alterations and altered signalling 
pathways are known to be recurrently associated with several types of tumours.  
The role of NF-κB signalling in thyroid cancer cell proliferation, invasion, and apoptosis has been 
reported. Our data provide a link between RAC1b overexpression and NF-κB signalling in thyroid 
cancer and address the consequences of this RAC1b-induced NF-κB stimulation in thyroid cellular 
processes, highlighting the RAC1b ability to interfere with apoptosis and cell cycle progression, via NF-
κB activation. 
In sum, this work contributed to the characterization of a pathway apparently involved in thyroid 
tumorigenesis, which may constitute a progress in the search for new therapeutic targets in thyroid 
carcinomas.  
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VII. PERSPECTIVES 
 
Future studies are needed to clarify the oncogenic potential of RAC1b in follicular cell derived 
thyroid carcinoma tumorigenesis, as well as in the assessment of differentially altered pathways between 
FTCs and FTAs, due to overexpression of Rac1b found in the malignant lesions. 
To better understand the cellular alterations caused by RAC1b-induced NF-κB activation, in the 
future, it would be important to further analyse cell cycle progression by flow cytometry in order to 
confirm the statistical significance of our preliminary data. Moreover, other cellular functions, such as 
migration, could be evaluated to better elucidate the cellular processes affected by RAC1b 
overexpression in thyroid biological systems. In fact, testing different in vitro thyroid models could help 
us to confirm and better understand the differences in the mechanisms behind RAC1/1b role in thyroid 
cancer cells compared to thyroid normal cells.  
The evaluation of the levels of activation of the NF-κB transcription factor in patient tumour samples 
with Rac1b overexpression would be helpful to corroborate the ability of this GTPase to stimulate the 
NF-κB pathway in thyroid tissue, in an in vivo setting. An immunohistochemistry approach can enable 
us to assess, in paraffin preserved tissues, the differences on subcellular localization of p65 protein on 
tumour vs normal cells, as well as between tumour cells with and without RAC1b overexpression.   
Recently acquired knowledge in the cancer field revealed that each specific type of neoplasia may 
be dependent on more than one altered signalling pathway. On that basis, the search for new pathways 
that might be affected by Rac1b expression and cooperate with the NF-κB altered pathway to modify 
cellular processes associated with tumour progression, may be decisive.  
The use of high-throughput screening methodologies to identify new potential targets of RAC1b is 
a viable possibility. This approach can also be used in order to identify pathways which can be affected 
by the potential synergy between RAC1b and BRAFV600E mutation, an association suggested by previous 
studies in colorectal cancer and also by our group in thyroid (Matos et al., 2008; Silva et al., 2013). 
Overall, we hope that this work could contribute to the development of new treatments that target 
multiple pathways, for patients with follicular cell derived thyroid cancers. 
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APPENDIX 1 – Solutions prepared for the experimental work: 
Table 4. 10x PCR buffer. 
Reagents Final Concentration 
Tris-HCl 100 mM 
KCl 500 mM 
MgCl2 15 mM 
Gelatin 0,1% (w/v) 
 
Table 5. RIPA buffer. 
Reagents Final Concentration 
Tris-HCl 20 mM 
NaCl 150 mM 
KCl 5 mM 
MgCl2 5 mM 
Triton X-100 1% (v/v) 
Complete, Mini, EDTA-free 
Protease Inhibitor Cocktail 
1 tablet per 10 mL 
solution 
pH 7,5 
 
Table 6. 5x Sample buffer. 
Reagents Final Concentration 
Tris-HCl 200 mM 
SDS 10% (w/v) 
DTT 325 mM 
Glycerol 25% (v/v) 
Bromophenol blue 0,05% (w/v) 
pH 6,8 
 
Table 7. Blot buffer.  
Reagents Final Concentration 
Tris 25 mM 
Glycine  192 mM 
SDS 0,03% (w/v) 
Methanol 5% (v/v) 
pH 7,6 
 
Table 8. Destain solution.  
Reagents Final Concentration 
Acetic acid 10% (v/v) 
Methanol 45% (v/v) 
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Table 9. TBST solution. 
Reagents Final Concentration 
Tris-HCl 50 mM 
NaCl 150 mM 
Triton X-100 15 mM 
pH 7,6 
 
Table 10. ECL solutions.  
Reagents 
(Solution 1) 
Final Concentration 
Reagents 
(Solution 2) 
Final Concentration 
Tris pH 8,8 100 mM Tris pH 8,8 100 mM 
Luminol 3,75 mM Hydrogen Peroxide 0.1% (v/v) 
Cumaric acid 450 µM 
Solution 1 and Solution 2 are mixed 
immediately before use. 
 
Table 11. Annexin binding buffer 1x. 
Reagents Final Concentration 
HEPES 0,01 M  
NaCl 0,14 M 
CaCl2 2,5 mM 
 
Table 12. PI solution cell cycle assay. 
Reagents Final Concentration 
PI  50 µg/mL  
RNase  0,1 mg/mL  
Triton X-100 0,05% (v/v) 
 
